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Abstract 
 
The integrin αvβ3 is part of a family of membrane proteins with bi-directional 
signalling and activity. In this way αvβ3 plays an extensive and complex role in 
cancer biology. This study builds on results that show that knocking out αvβ3 in 
endothelial cells reduces cancer metastasis suggesting that endothelial αvβ3 plays 
a pro-metastatic role. In particular, there has been a focus on the pre-metastatic 
niche, a pro-metastatic environment set up by the primary tumour before metastatic 
growth. In this vein, changes to pre-metastatic environments have been studied via 
immune cell and cytokine profiling. To do this FACS and quantitative analysis of 
immunohistochemistry has been performed. While this study does not bring about 
a conclusive explanation of the pro-metastatic role of endothelial αvβ3, it opens up 
other areas of research. These include identifying changes in specific myeloid 
populations such as polarised neutrophils and identifying differences in the 
endothelial layer at metastatic sites.  
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1. Introduction 
 
1.1 Cancer 
 
1.1.1 Cancer 
 
Cancer is a family of diseases characterised by the uncontrolled and inappropriate 
proliferation of cells. They may form primary tumours and then, with the 
development of invasive properties, spread throughout the body and invade organs 
leading to secondary tumour formation.  Cancer is the second most common cause 
of death in the developed world. Its prevalence in these regions (number of people 
affected at any one time) is 6 million and the mortality (annual number of deaths) is 
2.9 million (Globocan, 2012). Costs to national healthcare systems are extremely 
high; for example, in the UK the cost to the economy is £18.3 billion annually 
accounting for the cost of health care and loss of productivity (Department of Health, 
2015).  
 
There are a number of risk factors that increase the chance of the development of 
a cancerous tumour, both environmental and genetic. The environmental factors are 
wide including obesity, alcohol, age and cancer causing substances (National 
Cancer Institute, 2015). Understanding these risk factors has been an important 
factor in reducing incidence of preventable cancers. These increase the chance of 
developing cancerous mutations as do a number of hereditary conditions (which can 
pre-dispose a person to developing cancer). These are frequently linked to a family 
history of cancer. 
 
 
 
Figure 1: How the tumour develops and invades a tissue as it progresses 
through the stages of bowel cancer (Knowles and Hurst, 2015) 
 
Cancer is a highly complex disease that has been a focus of research funding for 
many years. Most (approximately 85%) cancers arise from epithelial cells (Cancer 
Research UK, 2014) but it can present in a wide range of tissues, organs and cells 
including the bone marrow. This variety leads to a variable molecular profile and, in 
clinical practice, several grades of severity. These are scored from grade I to grade 
IV, the latter being the most invasive and likely to metastasise. In bladder cancer for 
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example stage I involves the invasion of the epithelial basement layer and in stage 
II cancer invasion of the muscle is evident. At stage III the cancer invades the 
perivascular tissue and at the most invasive stage IV the cancer progresses furthest 
invading new tissues and beginning to metastasise (Knowles and Hurst, 2015). The 
pathology of these stages is shown in Figure 1.1. 
 
Despite the many complexities and differences in cancers of different stages and 
different tissue types there are a number of commonalities. These facilitate the 
switch of cells from normalcy to malignancy and the multi-step process of cancer 
progression.  
 
1.1.2 Tumour Initiation  
 
It is widely accepted that the origination of a cancerous tumour can be ascribed to 
mutations in three families of cancer initiating genes. First, the proto-oncogenes 
(e.g. c-myc or ras), where a mutation leads to overexpression of the protein and 
promotion of cell growth. Second, tumour suppressor genes (e.g. APC), where a 
mutation of both alleles is necessary to prevent this gene family’s negative 
regulation of cell growth or the genes that control it. Thirdly, in many hereditary 
cancers, mutations in the DNA repair genes allow an increased probability of 
mutations in proto-oncogenes and tumour suppressor genes (e.g. the cell cycle 
repressor Rb) (Tsynes and Bjerkvig, 2007).  
 
These mutations that will result in the gain or loss of function can modify the gene 
itself or lead to a change in a separate oncogenic or tumour suppressive gene 
product that influences gene expression. The alterations will affect the activity of a 
cancer related protein at one of three levels; genomic transcription, protein 
translation or post translational modifications. Most fundamentally, there can be 
changes in the gene itself such as base pair deletions or chromosomal 
translocations that can lead to mutated proteins. The transcription, and 
consequently the translation, of a gene can also be increased or decreased in a 
number of ways including changing the activity of transcription factors, such as p53, 
or epigenetic modifications such as gene silencing. Finally, post-translational 
modifications such as phosphorylation and ubiquitination by other proteins can 
modify the function of a cancer related protein so that its signalling pathways are 
over or under-active (Fernald and Kurokawa, 2013). 
 
With any of these genetic alterations, tumour initiating cells are formed which will 
then undergo unrestrained clonal expansion, the first step of carcinogenesis. There 
are some suggestions that these cells have stem like properties (known as cancer 
stem cells) with the ability to self-renew and differentiate (Medema, 2013). In this 
linear model of carcinogenesis as the daughter cells are produced, more mutations 
occur that facilitate the progression of the tumour to malignancy. In 1976, Nowell 
suggested that, as these daughter cells produce more aggressive phenotypes, they 
are selected for in an evolutionary process. The mutations and consequent 
phenotypes that support cancer progression have been researched in great depth.  
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1.1.3 Cancer Progression 
 
Carcinogenesis is a multi-step progress where a tumour acquires a number of 
essential characteristics, or “hallmarks” developing intra tumoural heterogeneity. 
The aggressive phenotype that the daughter cells gain relies on the accumulation 
of cancer supporting mutations in the tumour cells.  
 
Part of this evolution of the tumour is thought to be enabled by genomic instability 
which confers an increased mutative potential on the cells. The cause of this 
emerging cancer supportive mechanism is still debated but the stage and type of 
cancer has been shown to reflect the underlying cause. The mutator hypothesis, 
which seems to mainly be associated with hereditary cancers, suggests that 
mutations in the DNA repair genes, mentioned previously, grants an increased 
mutation rate (Negrini et al., 2010). In non-hereditary cancer, at least at an early 
stage, the oncogene-induced DNA replication stress model, a form of chromosomal 
instability, has been proposed (Negrini et al., 2010). This hypothesis suggests that 
the increased replicative potential that oncogenes have upon the cell leads to 
replicative stress that is characterised by stalled and collapsed replication forks. As 
the tumour progresses further factors then contribute to genomic instability (Hills 
and Diffley, 2014). 
 
After the initial growth and mutations, tumours can remain dormant for years due to 
a balance between proliferation and growth suppressing mechanisms. Overcoming 
these growth suppressive mechanisms is an essential step on the path to 
malignancy.  Growth suppressing pathways include negative feedback loops that 
disrupt proliferative signalling, senescence (where cells enter a non-proliferative yet 
viable state), and pathways of programmed cell death (Hanahan and Weinberg, 
2011).  
 
There are three main forms of programmed cell death; programmed necrosis (a form 
of cell lysis), autophagy (the breakdown of a cell via the fusion of autophagosomes 
with lysosomes), and apoptosis (Ouyang et al., 2012; Hanahan and Weinberg, 
2011). The most studied of these is apoptosis, which presents a barrier that must 
be overcome as a part of multi-step carcinogenesis. The ability to circumvent 
apoptosis is a possible mechanism by which certain cancers, such as pancreatic 
ductal adenocarcinoma, can gain resistance to non-surgical therapies (Arlt et al., 
2013). The constant stresses that carcinogenesis puts upon a tumour cell can lead 
to the entrance of programmed cell death pathways. These stresses include 
genomic instability, proliferative signalling and DNA damage (such as that 
suggested by the oncogene induced DNA replication stress model) (Fernald and 
Kurokawa, 2013).  
 
Apoptosis is regulated in a number of ways, via stimuli (such as FasL and TRAIL), 
inhibitors (like the Bcl-2 family), and promoters (such as Bax) (Arlt et al., 2013). All 
of these can be influenced by upregulating or limiting their expression to overcome 
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apoptosis in the tumour. One of the most common mutations in a tumour, however, 
is mutation of the transcription factor p53, a tumour suppressor gene that leads to 
cell cycle arrest and eventually apoptosis as part of the DNA damage response. 
This gene has been shown to have a particularly significant role when mutated in 
carcinogenesis by evidence that its presence increases susceptibility to 
spontaneous tumour formation in p53-/+ transgenic mice (Lee and Bernstein, 1995). 
Once these growth suppressors have been disabled the cancer cell gains 
“replicative immortality” which is proposed as a hallmark of cancer by Hanahan and 
Weinberg (2011).  
  
When the tumour overcomes the mechanisms that prevent the over-proliferation of 
cells and reaches this hallmark it must support its excessive proliferation for the 
tumour to grow. For this the tumour needs an environment rich with growth factor 
ligands, such as members of the FGF and HGF families, which stimulate the 
proliferative signalling pathways of the cells. A number of sources can be used to 
supply these growth factors. One such source is the surrounding stromal cells such 
as fibroblast and immune cells which support mitogenic tumour signalling in a 
paracrine manner (Bhowmick et al., 2004; Coussens and Werb, 2002). On the other 
hand, tumour cells can adapt so that they themselves produce ligands to stimulate 
their proliferative signalling in an autocrine manner (Hanahan and Weinberg, 2011). 
 
A second mechanism that is essential for sustaining cancer proliferation is the 
development of a tumour vasculature. As the tumour grows it reaches a size where 
passive diffusion alone is not enough to oxygenate a tumour. At this point, which 
occurs at a very early stage of tumour development, the formation of a 
neovasculature associated with the tumour is essential. Without this new network of 
blood vessels, the tumour cannot grow past 1 – 2 mm3 so, beyond this, tumour 
growth is angiogenesis-dependent (Folkman, 1989). The inhibition of tumour 
angiogenesis has been studied as a potential therapeutic mechanism, and cellular 
markers of angiogenesis have been investigated as possible therapeutic targets.  
 
There are a number of ways that this new vasculature can be produced including 
vasculogenesis, and vascular mimicry. Vasculogenesis is the de novo formation of 
blood vessels using endothelial cell progenitors. There is evidence showing that the 
inhibition of endothelial precursor activity prevents the initial angiogenic response 
but whether this effect is directly angiogenic, or whether endothelial precursors 
support angiogenesis in other ways, is debated (Fox et al., 2007). On the other hand, 
vascular mimicry is where tumour cells mimic an endothelial phenotype forming 
vascular-like vessels (Hendrix, 2015). While there is some evidence for these 
processes, much remains unclear and vascular remodelling via angiogenic 
mechanisms remains the most studied and prevalent response in forming a tumour 
vasculature.  
 
Angiogenesis is the creation of new blood vessels from a pre-existing vasculature. 
There are two main forms; sprouting where new blood vessels grow off of old 
vessels in response to stimuli, and intussusception where a pre-existing vessel splits 
into two (Carmeliet and Jain, 2000). A number of co-ordinated steps are involved in 
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angiogenesis. The vessel permeability is increased thereby destabilising the 
vasculature and supporting the prospective remodelling. The basement membrane, 
a specialised extracellular matrix, is digested facilitating the migration and invasion 
of endothelial cells. These cells then proliferate in sprouting angiogenesis and form 
new capillary lumen. In the final stages of angiogenesis pericytes are attracted 
forming a new basal lamina and the capillaries stabilise and mature (Wong et al., 
2009; Nishida et al., 2006).  
 
Controlling the expression of a number of oncogenes and tumour suppressor genes 
can cause a pathological state of angiogenesis in the tumour by affecting the 
expression of angiogenic factors. Examples include Ras, myc and v-raf, which can 
upregulate angiogenic factors (Fox et al., 2007), and p53 which suppresses VEGF 
(VEGF-A) and increases TSP-1 expression (Liekens et al., 2001). Angiogenesis is 
controlled by the presence of these pro- and anti- angiogenic factors (Liotta et al., 
1991), regulating this multi-step process at a number of levels. Pro-angiogenic 
factors include proteases that facilitate the breakdown of the basement membrane 
(BM), MMP-9 which digests type IV Collagen and MMP-2 which digests laminin, and 
integrins such as αvβ3 and αvβ5 which regulate endothelial cell interactions with the 
ECM (Liekens et al., 2001).  
 
One of the most significant factors in angiogenesis is VEGF which binds to VEGFR2 
on endothelial cells and supports migration, proliferation and survival, as well as 
inducing vascular leakage (Yancopoulos et al., 2000). This factor is produced by 
most cells but, under the hypoxic conditions frequently prevailing in the tumour, it 
can be upregulated by tumour associated macrophages, endothelial cells and 
tumour cells leading to an angiogenic response (Claesson-Welsh and Welsh 2012; 
Liao and Johnson, 2007). There are also a number of anti-angiogenic factors that 
negatively regulate angiogenesis including TSP-1 and endostatin, both of which 
decrease migration and increase apoptosis of endothelial cells (Liekens et al., 
2001). The balance of these factors determines whether the angiogenic switch is 
‘on’ or ‘off’ and the imbalance in the tumour which causes the constant ‘on’ state of 
the angiogenic switch leads to an abnormal and disorganised vasculature (Liao and 
Johnson, 2007). This is characterised by excessive permeability, intermittent and 
chaotic blood flow, a lack of protective pericytes and smooth muscle cells, and a 
high turnover of vessels (Carmeliet and Jain, 2000; Claesson-Welsh and Welsh, 
2012). Such disorganisation in the vasculature means it is a poor oxygen delivery 
system causing hypoxic regions in the tumour which in turn, leads to persistent 
production of VEGF (Fox et al., 2007). The disorganised vascular also presents a 
barrier to effective penetration by potential therapeutic molecules. 
 
Another growing field of research is the investigation of the role that infiltrating 
immune cells, such as tumour associated macrophages and neutrophils, play in 
supporting angiogenesis. With the VEGF induced increase in vascular permeability 
there is an increase in the numbers of tumour associated leukocytes (Claesson-
Welsh and Welsh, 2012). These cells produce angiogenic factors such as VEGF, 
MMP-9 and pro-angiogenic chemokines (e.g. CXCL8 and CXCL1) which perpetuate 
the pro-angiogenic state of the tumour environment (Tazzyman et al., 2009). 
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1.1.4 The Immune System and Cancer 
 
There has been much debate into the significance of the role played by the immune 
system in tumour development and whether that role is supportive or antagonistic. 
That there was a connection between cancer and the immune system was brought 
to the attention of scientists by a number of early observations made by medical 
scientists. An increased occurrence of cancer was detected at sites of chronic 
inflammation, and a link was established between disease regression in cancer 
patients and increased activity of the immune system.   
 
For years, scientists have been attempting experimentally explore the anti-tumoural 
role that the immune system can play. One such example has been studies into the 
incidence of tumours in immunocompromised murine models and humans. One 
experiment used RAG1-/- mice which have compromised antigen organisation and 
presentation on T and B lymphocytes. These mice had an increased risk of 
developing MCA induced sarcomas and spontaneous epithelial malignancies in 
comparison to WT mice (Dunn et al., 2002; Prestwich et al., 2008). Studies using a 
mouse model deficient in another subset of lymphocytes, NK cells, also showed a 
significant increase in the frequency of spontaneous tumours (Prestwich et al., 
2008). There is also evidence from immunosuppressed transplant patients and 
immunodeficient patients that the immune system also plays a role in tumour biology 
in humans. For example, a Nordic study looking at the data of 5000 
immunosuppressed kidney transplant patients between 1964 and 1982 showed a 
2-fold to 5-fold increase in a number of cancers including lung, colon and prostate 
and a 30-fold increase in the prevalence of kidney cancer (Prestwich et al., 2008). 
Despite the complication caused by the prevalence of tumours of viral origin, overall 
such studies have shown the tumour antagonistic role that the immune system can 
play.  
 
It has been proposed that, as part of these antagonistic activities, the immune 
system detects and destroys cells undergoing neoplastic transformation in an effort 
to maintain homeostasis (Mellman et al., 2011). Known as the immunosurveillance 
theory, it was suggested that tumour initiation happens more regularly than the 
occurrence of detectable tumours would suggest. There appears to be a number of 
triggers that initiate these mechanisms in the immune system; ‘danger signals’ and 
tumour antigens (Mellman et al., 2011).  Endogenous signals, such as RNA/DNA, 
from stressed or dying cells in states such as hypoxia or necrosis, or cells targeted 
by NK cells which initiate cell lysis, will alert the immune system (Prestwich et al., 
2008). This allows the presentation of tumour antigens by antigen presenting cells 
that will lead to an immune response. Antigens are presented on the cell by 
membrane proteins such as HLA, in humans, and MHC, in mice (Rosenberg, 2001).  
They can be tumour specific antigens produced by mutations in genes, for example 
chromosomal translocations, or by post-translational modifications (Prestwich et al., 
2008). They can also be normal proteins with an abnormal expression profile, both 
increased and decreased (Tinn, 2012). Examples of tumour antigens include 
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MAGE-1 an antigen in testicular cancer, and p53, the expression of which is 
frequently reduced in tumours (Rosenberg, 2001).  
 
 
Figure 2: The regulation of the immune system during tumour development. 
This image shows how anti-tumour immunity can be developed by tumour 
antigens and the regulation of this response by immunosuppressive cells such as 
Treg cells (Mellman et al., 2011) 
 
The predominant mechanism behind the anti-tumour immune response initiated by 
these factors is adaptive immunity, much of which is shown in Figure 1.2. This is 
based on the production of tumour infiltrating lymphocytes with anti-tumour 
immunity, the presence of which correlates to a better prognosis (Mantovani et al., 
2008). To generate these, antigen presenting cells (APCs) such as dendritic cells, 
must be exposed to tumour antigens which they then collect (Krieg and Boyman, 
2009). The APCs then present the tumour derived fragments to immature 
lymphocytes in the lymph nodes such as CD4 T helper cells and CD8 cytotoxic T 
cells. With the stimulus these cells are activated and undergo clonal expansion 
before homing to and infiltrating the tumour (Finn, 2012; Mellman et al., 2012; 
Pardoll, 2012). The relevance of such cells in humans was shown in an 11-year 
study in Japan that followed 3625 individuals predominantly older than 40. They 
found that higher cytotoxic activity of peripheral blood lymphocytes, assessed by a 
chromium release assay and immunological markers, was associated with 
decreased risk of cancer (Imai et al., 2000).  
 
This anti-tumour immune response that seems to be in a large part mediated by 
lymphocytes, is reliant on chemokines and cytokines produced by immune cells. 
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These membrane bound and secreted proteins play a number of roles in the tumour, 
including the homing of immune cells, and the stimulation of intracellular signalling 
pathways that manipulate the activity of both immune and stromal cells. One 
cytokine that has been of particular scientific interest has been IFN-γ, which is 
released by T effector cells. This protein exerts an anti-proliferative and pro-
apoptotic influence on tumour cells as demonstrated in IFN-γ KO mice which have 
been shown to have an increased risk of both spontaneous and chemically induce 
tumours in comparison to WT mice (Prestwich et al., 2008; Dunn et al., 2002). IFN-
γ also stimulates the expression of CXCL-9, -10, and -11 by T-lymphocytes which 
also support anti-tumour immunity by facilitating the homing of lymphocytes and 
exerting angiostatic effects on endothelial cells (Liu et al., 2011). Chemokines play 
an important part in immunity by directing immune cells that express specific 
receptor to sites of inflammation. One example is CCL21 which attracts leukocytes 
via its receptor CCR7 and plays a part in inducing T effector cell infiltration (Krieg 
and Boyman, 2009). Understanding how this process of anti-tumour immunity works 
has been important in the development of potential therapies. 
 
Overall, it is the immunogenicity of a tumour that will determine the success of the 
immune response in combating the malignancy. Based on this concept there have 
been a number of attempts to harness these elements of the immune system to 
develop cancer immunotherapies. The idea that the immune system could be 
harnessed for clinical benefit was proposed years before the theory of 
immunosurveillance in the 1890s by William Coley, a surgeon. He carried out a 
procedure, known as Coley’s toxin treatment, in which he injected patients with 
attenuated strains of Streptococcus pyogenes (Mellman et al., 2011). Though 
inconsistent results have been obtained using this treatment, it marked the 
beginning of a long struggle to use the immune system against cancers. Cancer 
immunotherapy has been approached from a number of angles; passive, where a 
pre-existing and active immune response is enhanced, and active, where 
components of the immune system are activated.  
 
One example of passive immunotherapy is the antibody rituximab which increases 
B cell lymphoma identification by components of immune system (Finn, 2012). 
Another is the use of vaccines such as peptide vaccine based on tumour antigens. 
These can be combined with cytokines such as IL-2 to increase their effectiveness 
(Rosenberg, 2001). Cytokines can also be taken advantage of by active 
immunotherapies such as the intra-tumoural injections of gene modified dendritic 
cells that overexpress active CCL21. This therapy has gone through Phase 1 pre-
clinical trials for non-small lung cell carcinoma and has been shown to induce CD8+ 
T cell infiltration (Lee et al., 2014). Another cell-based method of immunotherapy is 
the exposure of immune cells (such as dendritic cells) to tumour antigens ex vivo 
and the re-injection of these tumour targeting cells into patient (Krieg and Boyman, 
2009). A Phase I/IIa clinical study exposed autologous dendritic cells to multiple 
tumour associated antigens, including MAGE-1, left 9 of 12 patients who had 
undergone previous clinical treatment tumour free up to 24 weeks and increased 
the tumour-specific immune response (Lee et al., 2015). One example of success 
in immunotherapy has been the preventative human papilloma virus vaccines based 
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on the E6/E7 antigens (Rosenberg, 2001), which are available on the NHS. These 
target the oncogenic virus rather than harnessing the immune system against the 
cancer itself. Overall there has been limited success but with increased 
understanding of the relationship between cancer and the immune system the 
number of clinical trials of immunotherapies is now rapidly increasing. Indeed, 
several novel drugs with immune targets have recently been approved for clinical 
use (Kwek et al., 2012; Schmidt, 2015).  
 
It has now been shown that the interaction between tumours cells and the immune 
system is not simple, and that tumours can in fact respond to challenge and evolve 
to evade destruction. According to immunoediting hypothesis, there are three stages 
that a cancer will go through in its relationship with the surveillance components of 
the immune system; elimination, equilibrium and escape. Elimination is the anti-
tumorigenic behaviours of the immune system shown above. In equilibrium the 
tumour goes through cycles of growth and destruction by the immune system. 
Finally, escape is where the tumour enters a state where it avoids destruction by the 
immune system (Dunn et al., 2002). 
 
The destruction of tumour cells that is associated with elimination and equilibrium 
exerts a selective pressure on cancer cells that enables them to enter into a new 
relationship with the immune system known as escape. There are a number of 
genetic changes to tumour cells themselves that will enable them to avoid immune 
surveillance. These include the downregulation of antigen presenting receptors, and 
suppressing the activity of signalling pathways that enable immune destruction such 
as impaired perforin binding or downregulating the Fas receptor. Tumours may 
reduce stimulatory signals such as danger signals and co-stimulatory molecules so 
that the immune response is attenuated (Prestwich et al., 2008; Rosenberg, 2001). 
A number of immunosuppressive cytokines, such as TGFB and IL10, can directly 
decrease the activity of immune cells by inhibiting the function and activation of anti-
tumour cells (Krieg and Boyman, 2009; Coussens and Werb, 2002). These factors 
can be produced by tumour cells or by cellular components of the immune cell that 
regulate the inflammatory response. Examples of such cells include regulatory T 
cells, which interfere with effector T cell function and produce immunosuppressive 
factors, myeloid derived suppressor cells which suppress the cytotoxic activity of 
CD8+ T and NK cells, and tumour associated macrophages (Mantovani et al., 2008; 
Krieg and Boyman, 2009; Prestwich et al., 2008).  
 
Part of this anti-inflammatory response, is the hijacking of mechanisms that are 
essential in preventing auto-immune diseases. Other examples of homeostatic 
regulatory proteins involved in cancer immune escape are the immune checkpoint 
proteins. In tumour biology PD1, found on T cells, binds to the PDL-1 ligand, 
expressed by untransformed epithelial cells and by tumour cells, forming a complex. 
It is known that this inhibits lymphocytic cell function and hides tumour cells from the 
immune system, though the intricacies of this mechanism are still unclear (Schmidt, 
2015; Pardoll, 2012). While PD1 regulates effector T cell activity, other immune 
checkpoint proteins regulate their activation. On such protein is CTLA4, which plays 
a part in co-stimulation of T cells by antigen presenting cells and dampens the 
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tumour specific T cell response. T lymphocytes are activated by APCs by a co-
stimulatory mechanism; TCR recognises its cognate antigen and CD28 binds to 
CD80/86 amplifying TCR signalling. Upon T cell activation by APCs CTLA4 is 
transcribed and expressed on the surface of the cell at sites of APC/T cell 
engagement. This protein also binds to CD80/86 and with a greater affinity thereby 
dampening the activation response (Kwek et al., 2012; Pardoll, 2012). The discovery 
of these has brought about a number of cancer immunotherapies that enhance the 
immune response by overcoming immune checkpoints. Examples include 
ipilimumab (CTLA4) and nivolumab (PD1), both of which have been approved by 
the FDA for clinical use (Schmidt, 2015).   
 
As with the anti-tumour components of the immune system, tumour supportive 
inflammation does not only help to control anti-cancer inflammation but can directly 
influence the steps in the progression of a tumour described earlier. The increased 
incidence of colon cancer in chronic inflammatory colon diseases such as Crohn’s 
Disease and Chronic Ulcerative Colitis is one example of evidence that supports 
this (Coussens and Werb, 2002). A particularly well studied constituent of pro-
tumorigenic inflammation, mentioned earlier, is tumour associated macrophages 
(TAMs). The polarisation of macrophages to TAMs is induced by a number of 
cytokines including IL-10, produced by tumour cells, tumour associated stromal cells 
and T regulatory cells (Mantovani et al., 2008). Apart from suppressing the adaptive 
immune response these cells can promote tumour development by the production 
of pro-tumorigenic cytokines. These include MMPs which support tissue 
remodelling, VEGF which is plays an important role in angiogenesis, and growth 
factors that stimulate cancer growth. Finally, TAMs have been shown to increase 
the metastatic potential of a cancer (Noy and Pollard, 2014). 
 
1.1.5 Metastasis 
 
It is not primary tumours that cause the majority of cancer deaths; rather it is the 
metastatic burden which results in 90% of cancer mortalities (van Zijl et al., 2011). 
As the tumour proceeds down the road of carcinogenesis it develops the hallmarks 
and mechanisms that support its proliferation. The hallmarks described previously 
are frequently shared with benign tumours, but the ability of a cancer to invade new 
organs and metastasise is not, making this the most definitive characteristic of 
malignancy. The complexity of the metastatic process, which involves many steps, 
means that only a small proportion of cells metastasise successfully, yet metastases 
are established as the numbers of malignant cells involved is so large.  
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Metastasis, leading to secondary tumour formation, occurs through three main 
processes; invasion, intravasation and extravasation and the steps involved in these 
processes are broken down in Figure .3. The 
first mechanism involved in metastasis is the 
dissemination of cells from the primary tumour 
by changes to the adhesive properties of 
tumour cells. This increases their motility and 
allows their migration to a transport system. 
The basement membrane and extracellular 
matrix surrounding the system is invaded so 
that the cells enter a circulatory system, either 
the lymphatic or vascular system. Upon 
entering the circulatory system cancer cells 
evade the immune system until they reach a 
site where they can bind to the endothelium. At 
this point a secondary tissue is invaded where 
the metastatic cells will proliferate and set up a 
secondary tumour. This metastatic process has 
been dubbed the metastatic cascade.  
 
 
 
Figure 3: The steps of the metastatic cascade 
and the processes involved in each of these 
steps (Gupta and Massagué, 2006) 
 
There are a number of factors that will cause a transformation to a metastatic 
phenotype in tumour cells and the subsequent mechanisms that comprise the 
metastatic cascade. Examples of pressures that select for a metastatic phenotype 
are hypoxia, reactive oxygen species and the immune system. When oxygen is low 
and cells become hypoxic the HIF-1 protein is stabilised and promotes angiogenesis 
and invasion by promoting the expression of proteins such as CXCR4 and LOX. 
With these factors the cells metastasise in a number of complex and not necessarily 
successful steps that are described below (Gupta and Massagué, 2006). 
 
Epithelial cells have a number of junctions that facilitate their attachment to other 
cells. When cells undergo carcinogenesis the up/down-regulation of specific 
proteins within these adhesion complexes controls cell-cell interactions and the 
ability of a tumour cell to successfully metastasise. Tumour cells are thought to be 
less adhesive than normal, homeostatic epithelial cells but there are a number of 
mechanisms that will encourage development of this phenotype (Oppenheimer, 
2006). One such mechanism of particular interest that regulates this detachment is 
the epithelial to mesenchymal transition (EMT), specifically Type III EMT (Martin et 
al., 2000). In this process cells switch from a highly connected epithelial phenotype 
to a detached mesenchymal phenotype. EMT can be stimulated in cells by a number 
of proteins including TGFβ and FGF. Recently a role for microRNAs has also been 
discovered in regulation of this process. These proteins have been shown to have 
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a number of effect such as inducing the expression of a number of transcription 
factors including Snail, Slug, Twist and ZEB1 which activate the EMT programme 
(Kalluri and Weinberg, 2009). This can lead to the dissociation of B-catenin from 
adheren junctions, cell-cell junctions which contain the critical adhesion proteins 
cadherins, and link the actin cytoskeleton to the cell membrane. With B-catenin no 
longer sequestered in the cytoplasm it can be influenced to translocate to the 
nucleus where it leads to the expression of metastasis supporting genes (Xu et al., 
2009). One of the most definitive changes to the cell during EMT is the change of 
these adheren junctions with loss of E-cadherin expression, which has adhesive 
functions, and the increased expression of N-cadherin, which encourages a 
migratory phenotype. There are a number of experiments that show the link between 
decreased expression of this E-cadherin and the invasiveness of cancer cells 
(Cavallaro and Christofori, 2001; Bremnes et al., 2002).  
 
During EMT there is a rearrangement of the cytoskeleton whereby cells lose their 
epithelial arrangement and gain a migratory phenotype that supports their 
movement from the primary tumour to a transport system (Farahani et al., 2014). 
When carcinoma cells move they undergo a complex process of extension and 
retraction based on the dynamism of the cytoskeleton. Actin polymerisation leads to 
the extension of the leading edge of the cell via Rac-1 dependent protrusions that 
are functionally equivalent to lamellopodia. These form integrin based focal 
adhesion with components of the ECM. This leads to actomyosin contraction, and 
the disassembly of focal contacts and retraction at the trailing edge (Yamaguchi et 
al., 2005; Gupta and Massagué, 2006; van Zijl et al., 2011). Cancer cell migration 
is directed towards a transport system that is incorporated into the tumour by 
lymphangiogenesis by VEGF-C and VEGF-D (van Zijl et al., 2011), and the 
angiogenic switch. One way that the direction of this migration is mediated has been 
shown in breast carcinoma in vivo by the interaction of tumour-associated 
macrophages with carcinoma cells. To attract TAMs to the tumour the cells secrete 
CSF-1 which acts a chemoattractant for macrophages expressing the receptor that 
exists in the vascular system. Once the macrophage receptor binds CSF-1 it 
secretes EGF which is a chemoattractant for the breast cancer cells which express 
EGFR (Condeelis and Pollard, 2006). It has been shown that EGF can then 
stimulate migration by upregulation of cofilin and components of the Arp2/3 complex 
that facilitate actin polymerisation (Yamaguchi et al., 2005). In this way TAMs can 
act as a guide for cancer cell migration towards the vascular system. It has also 
been proposed that VEGF in its role as a vascular permeability factor can increase 
the number of cancer cells in transport systems by negatively regulating tight 
junctions in the vascular endothelium. Another mechanism of guiding tumour cells 
in the lymphatic system has been suggested to be based on the CCL21-CCR7 axis 
that mediates homing of lymphocytes to lymph nodes during an immune response.  
 
Upon reaching a transport system cancer cells penetrate it in a process known as 
intravasation. As part of the EMT the expression of a number of proteases is 
upregulated by transcription factors such as Snail which increases the transcription 
of MMP-2 and MMP-9. These proteases not only digest components of adhesion 
protein complexes but, with a number of others including serine proteinases and 
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cysteine proteinases, they can cleave components of the extracellular matrix (Arya 
et al., 2006; Martin et al., 2010). When cells reach the transport system they adhere 
to the endothelial layer and form actin based protrusions known as invadopods that 
are rich in these proteins and which allows them to penetrate the basement 
membrane (Condeelis and Pollard, 2006). This enables them to reach the 
endothelial layer which they migrate through thus gaining entry to the vessels. 
 
Once cancer cells have successfully entered a circulatory system they experience 
such harsh conditions that only an estimated 0.1% of circulating tumour cells survive 
(Farahani et al., 2014). These adverse conditions include shear forces which can 
cause physical damage, and destruction by circulating anti-tumour immune cells 
such as Natural Killer cells (Arya et al., 2006; Oppenheimer, 2006). One 
mechanisms that tumour cells use to survive is the co-opting of platelets via integrin 
binding to form ‘clots’ that protect the cancer cells from both physical and immune 
stresses in circulation (van Zijl et al., 2011; Arya et al., 2006). 
 
Selectins expressed on endothelial cells plays an important role in the trans-
endothelial migration of leukocytes. Tumours can use a similar mechanism by 
upregulating the selectin ligands such as sLex and sLea (Farahani et al., 2014; Arya 
et al., 2006). This allows interactions between endothelial cells and tumour cells to 
be developed at this point as the first step of the second invasion process of the 
metastatic cascade, extravasation. Upon entering the secondary tissue, the 
mesenchymal phenotype is reversed back to an epithelial phenotype in a MET 
regaining an apical-basal cell polarity and cell-cell adhesion junctions (Martin et al., 
2010). 
 
This cascade of events is a highly complex process with a low success rate and 
when metastatic cells reach the secondary tissue there are a number of fates they 
can undergo. The metastatic cells may be successful and form interactions with their 
new environment enabling proliferation. They may also remain dormant for years or 
be destroyed due to environmental factors such as the adaptive immune system. 
The success of the cancer cells depends on the environment of the secondary tissue 
that they enter (Gupta and Massagué, 2006; Oppenheimer, 2006; Farahani et al., 
2006). As such, the formation of a pre-metastatic niche can improve the chances of 
proliferation and the setup of a successful metastatic tumour. 
 
1.2 Pre metastatic niche 
 
1.2.1 Pre- metastatic Niche Formation 
 
Metastasis is an inherently inefficient process with very few circulating tumour cells 
reaching the metastatic site. Even then these metastatic tumour cells may never 
lead to a secondary tumour (experiments show that only 0.02% of injected tumour 
cells form macrometastases (Massagué and Obenauf, 2016)) and in some cases 
tumour cells will remain dormant for many years. There is now a growing body 
evidence that the primary tumour may influence the secondary tissue so that it will 
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be favourable to the seeding and growth of metastatic cells. This environment has 
been called the dubbed the pre-metastatic niche.  
 
The idea that certain cancers more disposed/have greater success when 
metastasising to specific organs was noted many years ago. This was first described 
in 1889 by Stephen Paget who presented the ‘seed and soil’ hypothesis showing 
that the time, pattern and site of cancer spread is influenced by the cancer type. The 
frequency of metastasis could not be explained simply by blood supply suggesting 
a favourable soil. He argued that while the primary tumour is of great importance to 
the understanding of cancer, there should also be a concerted effort to understand 
the metastatic environment (Fidler, 2003). This was challenged by Ewing who 
hypothesised that the predilection of certain cancers for particular organs is 
explained by the anatomy lymphatic and vascular systems associated with the 
primary tumour (Psaila and Lyden, 2009).  While this has been the accepted theory 
for a number of years there is now a range of data that backs up Paget’s theory of 
a favourable soil. Fidler in particular was important in presenting some of the first 
evidence that the soil plays an important role. He showed that metastatic cells can 
be found in the capillary beds of multiple organs, but only at a select number of sites 
do metastases consistently develop (Peinado et al., 2011). This has been supported 
by Weiss (1992) who showed that while regional metastasis might be put down to 
anatomy, many metastasis (particularly distant metastasis) cannot be explained by 
blood flow demonstrating that distant metastasis is site specific. This recent focus 
on understanding the soil has led to the proposal of a pre-metastatic niche. 
 
Part of what determines where circulating tumour cells will arrest is their expression 
of different receptors and at this stage the seed is significant. Cancer cells can be 
directed to specific sites by homing mechanisms such as the CXCR4-CXCL12 axis 
(Mendoza and Khanna, 2009). The interactions of cells with the endothelium will 
then determine which organs the metastatic cells will enter in the docking and 
locking process. First the docking though selectins and then the firm adhesion 
though integrins such as αvβ3 which will bind with greater success to bone 
endothelium when expressed by prostate cancer cell lines (Cooper and Pienta, 
2000).  
 
After the identification of a permissible environment, it has been suggested that the 
pre-existing niche will assist in a number of processes that metastatic cells must go 
through before the establishment of a metastatic tumour. The mechanisms that 
facilitate this are summarised below and are described in detail in 1.2.2 and 1.2.3. 
First, invasion can be assisted by supporting invadopodia formation, and locomotion 
(Rafii and Lyden, 2006; Feller et al., 2012). The transition from a mesenchymal to 
epithelial phenotype can then be backed by factors that influence tumour signalling 
pathways (Quail and Joyce, 2013). With cells established in the secondary organ 
they then grow using stem cell growth pathways that are frequently overactive. This 
growth can be supported by the presence of pre-existing ligands of this pathway 
(Massagué and Obenauf, 2016). The pre-metastatic niche can also be influenced 
so that the angiogenesis switch is activated. As with the primary tumour, this will 
facilitate the formation of macro-metastases (Psaila and Lyden, 2009). In metastasis 
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tumour cells also remove themselves from the immunoprotective environment of the 
primary tumour when they metastasis. As such the pre-metastatic niche can support 
metastasis by mechanisms that protect from metastatic cells from the immune 
system (Sceneay et al., 2013). There are many links between the primary tumour 
niche and the pre-metastatic niche because of the similar process that the primary 
and secondary tumour must go through to progress. These all rely upon bone-
marrow derived cells and tumour derived secreted factors which determine the state 
of a pre-metastatic organ (Kruger, 2015). 
 
1.2.2 The Role of Cytokines in the Pre-Metastatic Niche 
 
The pre-metastatic niche is dependent on the existence of the primary tumour and 
the signals that it conveys. Most of these signals are cytokines and chemokines that 
will then activate tissue components to niche similar to the primary tumour with a 
pro-metastatic phenotype. This will decrease the chance of cells entering dormancy 
and enabling the metastatic progression though the mechanisms mentioned above.  
 
One mechanism mentioned above that supports some of the very first steps of 
metastasis is the CXCL12/CXCR4 and CCL21-CCR7 chemokine axis (Strieter, 
2001).  CXCL12 is a chemotactic factor that plays roles in the trafficking during 
inflammation of leukocytes that express the CXCR4 receptor. Some cancer cells 
also upregulate this receptor, particularly those that are predisposed to bone 
metastasis (Mendoza and Khanna, 2009). Tissues, including the lung, liver and 
bone, upregulate CXC12 in the mature pre-metastatic niche (Kaplan et al., 2006 a). 
There are multiple mechanisms that contribute to this upregulation including 
production by mesenchymal cells dues to hypoxia or tissue damage and as a 
consequence of TIMP-1 production from the primary tumour (Feller et al., 2012; 
Kruger, 2015). This then causes cancer cells to migrate chemotactically in site 
directed metastasis   
 
Other secreted components prime distant sites to support metastatic cancer cells 
such as MMP-9 and MMP-2. Both of these proteases are secreted from cells in the 
lung before metastatic cells enter the tissue (Kaplan et al., 2006 a). They cleave 
ECM components (e.g. MMP-2 cleaves collagen IV) contributing to the remodelling 
of pre-metastatic tissues (Psaila and Lyden, 2009). This supports the invasion of 
tumour cells and bone marrow derived cells (BMDCs) to these tissues, which they 
back further by in some cases acting as chemotactic factors (Zoccoli et al., 2012).  
 
A number of factors are secreted directly from the primary tumour such as TGFβ 
and TNFα. The later of these is an important component of a number of pre-
metastatic niche’s including the liver and lung (Kruger, 2015). As described above, 
this inflammatory cytokine depresses immune function by interfering with cytotoxic 
T cell function (Psaila and Lyden, 2009). This plays an important part in creating a 
hospitable environment for the establishment of secondary tumours. TGFβ can also 
induce the expression of S100A8 and S100A9, which are predominantly expressed 
in the lung pre-metastatic niche (Psaila and Lyden, 2009; Raffi and Lyden, 2006). 
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These inflammatory proteins are chemoattractants and lead to the secretion of the 
inflammatory cytokine TNFα via the protein SAA (Lukanidin and Sleeman, 2012). 
The importance of their role in site directed metastasis has been shown in vivo as 
when they are inhibited, metastasis specifically to the lung decreases (Raffi and 
Lyden, 2006). 
 
Changes in the architecture of the ECM is another important change in the pre-
metastatic niche directed by cytokines from the primary tumour. Fibronectin is one 
component that is upregulated and it is one of the first changes that can be observed 
at distant sites after the set-up of a primary tumour (Kaplan et al., 2006 b). This 
stromal protein is secreted by a number of cells including fibroblasts and fibroblast-
like cells, which proliferate and secrete fibronectin due to PIGF signals from the 
primary tumour (Kaplan et al., 2006 a). It plays a number of important roles acting 
as a directive signal for arriving BMDCs and as a scaffold for adhesion of BMDC’s 
and later tumour cells (Feller et al., 2012). Another ECM component important in the 
pre-metastatic niche is collagen type IV. As with fibronectin it supports the adhesion 
and recruitment of BMDCs. It is cross linked by LOX, a cytokine secreted by hypoxic 
primary tumour cells (Zoccoli et al., 2012). This protein has been shown to have 
important roles in regulating the ECM of the pre-metastatic niche, localising with 
fibronectin and oxidising specific lysine residues of collagen IV (Sceneay et al., 
2013). 
 
A number of changes to the endothelium are also evident in the pre-metastatic 
niche. First, there are changes to the expression of adhesion proteins mediating the 
attachment tumour cells and BMDCs, supporting extravasation. E-selectin and P-
selectin have been shown to be upregulated (Psaila and Lyden, 2009), as are VCAM 
and ICAM due to the effects of CXCL12 (Feller et al., 2012). Changes to endothelial 
cells are also produced during the activation of the angiogenic switch by secretion 
of pro-angiogenic factors such as VEGF and PIGF by the primary tumour (Sceneay 
et al., 2013).  
 
VEGF does not just facilitate the formation of a pro-angiogenic environment 
activating mature endothelial cells, it also plays an important part in the mobilisation 
of BMDCs to the pre-metastatic niche. A number of secreted factors in the pre-
metastatic niche play an important role in determining the role that the immune 
system plays in the pre-metastatic niche. The secreted factor G-CSF, for example, 
mobilises Ly6G+Ly6C+ granulocytic myeloid cells to the liver pre-metastatic niche 
(Kruger, 2015). One of their most important functions is the trafficking of BMDCs to 
the niche. These cells will then secrete factors themselves and support the 
development of the pro metastatic phenotype. 
 
1.2.3 Bone Marrow Derived Cells in the Pre-Metastatic Niche 
 
As described previously there is a complex relationship that is both antagonistic and 
supportive between the immune system and cancer. This relationship extends to 
the pre-metastatic niche. The arrival BMDCs to the niche is one of the most 
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significant steps and the cytokines secreted from the tumour will determine the 
immune profile of pre-metastatic organs. These cells, of which there are many types 
then secrete factors themselves along with fibroblasts co-opted to support niche 
progression. This leads to the arrival of more immune cells and creates an 
environment that supports the invasion, adhesion, survival and growth of metastatic 
tumour cells. 
 
A critical element in the creation of a pre-metastatic niche was discovered by Kaplan 
et al., in 2005. They discovered that bone marrow derived cells predict tumour 
metastasis arriving at pre-metastatic sites well before tumour cell. This was shown 
to be a site specific phenomenon as different tumour types would induce the 
mobilisation of VEGFR1+ BMDCs to specific tissues. At the pre-metastatic tissue 
these BMDCs then formed clusters of cells that attached to upregulated fibronectin 
via VLA-4 (α4β1). These BMDC clusters were observed not just in spontaneous 
metastasis transgenic mouse model but also human pre-metastatic tissue. They 
showed that mature VEGFR1 clusters, containing BMDCs, fibroblasts and 
fibronectin, supported tumour adhesion and growth. The importance of these 
clusters was further shown when they were disrupted with an anti-VEGFR1 antibody 
blocking cancer metastasis. With the importance of these BMDC clusters 
established they discovered that the primary tumour plays an important role in this 
process showing that media conditioned by a tumour can induce cluster formation. 
This, is likely due to factors secreted by the primary tumour, some of which were 
investigated by Kaplan et al. including Id3 and VEGF-A. The clusters themselves 
also released factors supporting tumour metastasis. One example of this was an 
increase in CXCL12 in the clusters supporting the homing of tumour cells to the 
niche. This occurs as the clusters mature, recruiting more cells, such as VEGFR-2+ 
endothelial progenitor cells, and the BMDCs themselves gain functional 
heterogeneity. The BMDCs recruited to these clusters included haematopoietic 
progenitors with maturational heterogeneity (for example some express CD11b). 
This article has been the foundation of much pre-metastatic niche research. 
 
Further defining the BMDC population in the pre-metastatic niche has been an 
important part of understanding it.  An important component of this population are 
CD11b+ myeloid cells, many of which are described in Figure 1.4. This is a 
heterogeneous population including macrophages, monocytes, neutrophils and 
mast cells (Joyce and Pollard, 2009). These cells are attracted by a number of 
elements in the pre-metastatic niche such as the cytokines S100A8 and S100A9 
which can be produced by endothelial cells upon stimulation by microvesicles 
(Sleeman, 2012).  Another important part of myeloid influx is the remodelling of ECM 
by Lox crosslinking of collagen IV. This provides a scaffold for CD11b+ encouraging 
their recruitment (Erler et al., 2009; Smith and Kang, 2013). These cells then secrete 
MMP-2 which cleaves collagen IV leading to further remodelling and the production 
of chemoattractive peptides which encourages the migration of more CD11b+ 
BMDCs in a positive feedback loop (Sleeman, 2012; Peinado et al., 2011). 
 
Of the myeloid cells one population that has been described in the pre metastatic 
niche is the CD11b+/Gr1+ BMDCs which are, again, attracted by S100A8 and 
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S100A9 (Sceneay et al., 2013). These markers are generally used to define the 
myeloid derived suppressor cells (MDSCs) which is a heterogeneous population of 
immature myeloid cells with immunoprotective capabilities (Mantovani and Sica, 
2010; Joyce and Pollard, 2009). They have been shown in the pre-metastatic niche 
by a study using media conditioned by hypoxic tumour cells rich in VEGF-A, MMP-
9 and CCL2. This caused an influx of certain BMDC populations into a pre-
metastatic niche. The cellular subsets included CD11b+/Ly6Cmed/Ly6G+, which 
defines the granulocytic subset of MDSCs, and immature NK cells with no cytotoxic 
activity (Sceneay et al., 2012). Monocytic MDSCs (CD11b+/Ly6Cmed/Ly6G+) are also 
found in the pre-metastatic niche and together these populations support 
angiogenesis and suppress T cell activity (Smith and Kang, 2013; Sceneay et al., 
2013) 
 
In the study of the pre-metastatic niche and the immune system, a number of 
similarities have been found with the primary tumour and one example of this is the 
importance of TAMs. This is another population of cells which, like MDSCs, are 
derived from the myeloid lineage. These cells have been shown to circulate after 
the set-up of the primary tumour and can be found in distant organs where along 
with a VEGFR1+ environment they provide a fertile site for metastasis (DeNardo et 
al., 2008). These cells, as with other myeloid cells the influx of these cells is 
encouraged by ECM components such as versican and fibrin clots (Kruger, 2015; 
Kitamura et al., 2015). Once at the pre-metastatic niche it has been proposed that 
they perform a similar function as that in the primary tumour, creating a tumour 
supportive environment by encouraging a number of processes such as 
angiogenesis (Joyce and Pollard, 2009).  
 
Apart from the cytokines and angiogenic functions of immune cells the pre-
metastatic niche creates an immunoprotective environment. This is a particularly 
important role for BMDCs in the pre-metastatic niche. There are a number of 
immunosuppressive cells involved in this role, including MDSCs, which have been 
mentioned and CD4+ Treg cells, one of the few non-myeloid populations shown in the 
pre-metastatic niche (Kitamura et al., 2015). These two groups inhibit the cytotoxic 
T cell and NK cell mediated immune response (Sleeman, 2012). NK cells are 
important component of the immune system that can target tumour cells for 
destruction. There an increased number of immature NK cells in the pre-metastatic 
niche with no cytotoxic function suggesting that NK cell maturation is compromised 
in the niche (Sceneay et al., 2012).  It is possible that this is one mechanism of 
function for MDSCs and Treg cells. It has also been proposed that MDSCs reduce 
the expression of IFN-γ expression in the pre-metastatic niche due to MDSCs. This 
aligns with a Th2 cytokine shift that supports an anti-inflammatory phenotype (Yan 
et al., 2010). Furthermore, the MDSC population has been shown to produce TNFα 
which increases Treg numbers in niche (Kitamura et al., 2015). This co-operation 
supports the creation of environment that protects metastatic cells from anti-tumour 
components of the immune system.  
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Figure 4: The tumour secreted factors, cytokines and BMDCs involved in 
creating a pre-metastatic niche and how they support the colonisation and 
growth of metastatic tumour cells (Sceneay et al., 2013) 
 
The preliminary results describe a co-operation between primary tumour and 
secondary environment that is dependent on cytokines and the influx of BMDCs, 
with a particularly important role for myeloid cells. These BMDCs also release 
cytokines leading to the influx of further BMDCs in a positive feedback mechanism. 
This all leads to a tumour supportive environment that will encourage metastatic 
growth. This environment provides potential therapeutic options for preventing 
metastasis however there is still much to be discovered.  
 
1.3 Integrins 
 
1.3.1 Structure and Activation 
Integrins are transmembrane proteins with roles in cell processes such as adhesion 
that means they are important in a number of pathological diseases such as cancer. 
Understanding the structure and how the integrin is activated can lead to an 
appreciation of how this family of proteins plays a role in such diseases. 
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Integrins are heterodimeric proteins that consist of non-covalently associated α and 
β subunits (Luo and Springer, 2006). The integrin family subsists of type 1 
transmembrane glycoproteins with cytoplasmic, transmembrane and intracellular 
domains. They have a long ectodomain with a globular head that plays an essential 
part in integrin ligand binding and usually a short intracellular domain (Arnaout et 
al., 2005).  
 
The family of integrins contains 18α and 8β subunits that come together to for 24 αβ 
integrins shown in Figure 1.5. Half of the alpha subunits contain a von Willebrand 
Factor type A subunit (αI domain) that facilitates ligand binding. These 9 αI domain 
containing α subunits are indicated in Figure 1.5 by asterisks and for 9 of the 24 
integrins (Arnaout, 2005). 
 
Figure 5: The groups within the integrin protein family (Adapted from Luo 
et al., 2007)  
Red - leukocyte integrins, Black - RGD recognising integrins, Blue - collagen 
binding integrins, Green - a4/a9 cluster, Purple - laminin binding integrins 
 
The αI domain is the major ligand recognition site for integrins that have it and 
contains a metal ion dependent adhesion site (MIDAS) (Anderson et al., 2014). This 
motif on the α subunit has multiple binding conformations that are influenced by the 
binding of a ligand. Upon the binding of a ligand to the αI domain the MIDAS moves 
to an open conformation shifting a bound metal ion, such as Mn2+, so that ligand 
affinity increases. In the second, closed conformation, the metal ion is moved away 
from the binding sites used in the open conformation, consequently decreasing 
ligand binding efficiency (Luo et al., 2007; Liddington and Ginsberg, 2002).   
 
There are three families of α subunits that do not have the αI domain, the laminin 
receptors, RGD receptors and the α4/α9 cluster shown in Figure 1.5 (Anderson et 
al., 2014; Campbell and Humphries, 2011). In these integrins a second domain that 
is found directly on the β subunit, the βI/αI-like domain, acts with the β propeller on 
the α subunit as the major ligand recognition site (Liddington and Ginsberg, 2002). 
The β propeller also regulates the ligand binding activity of the α subunit in αI domain 
containing integrins (Anderson et al., 2014).  
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The αI-like domain acts in a similar way to the αI domain, containing a MIDAS motif 
that enables the β subunit to directly bind a ligand (Zhang et al., 2012; Luo 2006). It 
also has distinct open and closed conformations that allosterically regulate ligand 
binding. The β propeller ligand binding site is shielded by the α1-like domain when 
the protein is in a low affinity conformation. When a stimulus is present, a shift is 
induced so the β propeller ligand binding site is open (Hynes, 2002). 
 
1.3.2 Integrin Signalling and Activation 
 
Integrins signal in a bidirectional manner, capable of transmitting an intracellular 
signal extracellularly and vice versa. These signalling pathways are known as 
inside-out and outside-in signalling.  
 
In inside out signalling intracellular signals cause changes to the β cytoplasmic tail 
that lead to the activation or inactivation of the integrin. The different activation 
states lead to the binding of different cytoplasmic ligands that compete with each 
other for the same domains. This is controlled by the phosphorylation of NPxY motifs 
found on the cytoplasmic tail that ligands bind to via phosphotyrosine binding (PTB) 
domains. When the NPxY domain is phosphorylated it is inactive and proteins such 
as Dok1, which have a higher affinity for the phosphorylated NPxY domain bind to 
it. When the β tails are unphosphorylated and active, talin is able to bind to the tail 
setting up protein complexes (Anthis 2011; Oxley 2008). These cytoplasmic ligands 
interact with the β cytoplasmic tail disrupting its association with the α cytoplasmic 
tail allowing activation to take place. During activation there are conformational 
changes in the ectodomain that increases the affinity of the integrin to its 
extracellular ligands (Ginsberg and Shattil, 2005). 
 
These conformational changes are an essential part of controlling the activation 
state of an integrin. There are two current models of activation, the deadbolt model 
and the switch blade model. These models of activation are based on 
conformational changes between low affinity and high affinity states (Campbell and 
Humphries, 2011). 
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Figure 6: The domains and activation states of integrins (Anderson et al., 
2014) 
 
The two models debate the conformation change that occur in the integrin subunits 
during activation. Originally three integrin conformational states were proposed that 
relate to the activation state which are shown in Figure 1.6. The first of these is the 
bent or inactive state, which the association of the integrin tails maintains. In this 
conformation the α1 domain, β1 domain and the β propeller are bent closely to the 
cytoplasm. The second is the active state where the integrin is extended but the 
headpiece is closed. The third is the ligand occupied state with an open headpiece 
where conformational changes in the ligand binding site have occurred and the 
cytoplasmic tails and the transmembrane domains have separated (Ye et al., 2011). 
The deadbolt model on the other hand, suggests that less dramatic conformational 
changes occur and that once activated the integrin maintains its bent state but a 
change occurs that allows the ligand binding domains to be exposed (Mehrbod et 
al., 2013; Takada et al., 2007; Takagi et al., 2002). Despite there being evidence 
that suggest that integrins can bind ligands in the bent state current electron 
microscopy evidence seems to favour the switchblade model (Campbell and 
Humphries, 2011; Anderson et al., 2014) with some data seeming to contradict the 
deadbolt model (Zhu et al., 2007). Historically this has been one of the main focuses 
of integrin structure and activation but since this structural change only seems to 
apply to some integrins there has been attention on regulation of integrin activation 
by structural changes in the headpiece (Zhu et al., 2013). 
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The bi-directionality of an integrin means that signals can be propagated in a second 
manner, from the extracellular to the intracellular environment. In outside-in 
signalling ligands from the extracellular matrix bind to the head domain of the 
integrin which leads to intracellular signalling (Anthis and Campbell, 2011). Apart 
from the models described above, these signals are transduced by conformational 
changes such as the separation of integrin tail domains (Takada et al., 2007), and 
integrin clustering that is enabled by oligomerisation of the transmembrane domains 
of an integrin (Ginsberg et al., 2005). 
 
The transduction of an extracellular signal allows protein signalling complexes to 
develop at the cytoplasmic β tail which leads to the activation of intracellular 
signalling pathways. A protein family that plays an essential role in mediating 
integrin signalling is the Src family Protein Tyrosine Kinases (SFKs). SFKs bind 
directly to the β tail regulating the activation of kinases such as Focal Adhesion 
Kinase (FAK) via phosphorylation influencing cell migration and growth factor 
signalling (Harburger and Calderwood, 2009; Klinghoffer et al., 1999). 
  
1.3.3 The Signalling and Functions of Integrins 
 
The bidirectional signalling of integrins, means that integrins play a number of roles 
connecting the intracellular environment with the extracellular. These functions are 
both mechanical and chemical with ligands including extracellular matrix and 
cytoskeletal components and signalling molecules.  
 
The different integrins recognise a number of components of the ECM as ligands 
including fibronectin, collagen and laminin (Albelda and Buck, 1990). The 
intracellular tail of the integrin then forms attachments to the cytoskeleton, generally 
actin (Delon and Brown, 2007; Hotchin and Hall, 1995). This means that mechanical 
stresses in the external environment can be transmitted leading to reorganisation of 
the actin cytoskeleton and consequently the cell shape and polarity (Schwartz and 
Ginsberg, 2002). 
 
The connections that integrins form between cells and the extracellular matrix also 
facilitates their role in adhesion complexes and lamellopodia (Delon and Brown, 
2007). Generally, these are focal adhesions connecting to the actin cytoskeleton 
with the exception being α6β1 that connects to intermediate filaments in 
hemidesmosomes (van der Flier and Sonnenberg, 2001). Integrin adhesion and 
motility interactions are relevant to a number of cellular processes dependent on the 
locality and time of express. One example of integrin functions is the role of β2 in 
inflammation where it facilitates leukocyte adhesion in extravasation. In 
inflammation the integrins on leukocytes and their receptors on the endothelium are 
activated allowing leukocytes to adhere to the endothelial layer before extravasation 
(Hynes, 1992). 
 
The formation of complexes at the β cytoplasmic tails of integrins does not only 
facilitate the connections to cytoskeletal components. As mentioned previously, 
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talins and kindlins (Moser et al., 2009) play an important role in setting up these 
complexes separating the cytoplasmic domains of the α and β subunits. This allows 
the recruitment of further proteins after clustering including the IPP complex, 
containing integrin linked kinase, PINCH, and parvin, Paxillin, Vinculin, FAK and Src 
(Legate et al., 2006). These then lead to the activation of a number of pathways 
downstream of integrins (Danen and Yamada, 2001) and the signal that is 
transmitted is influenced by the ligand, ligand state and interactions with the ECM. 
The major signalling pathways that are influenced include the small GTPases, 
PI3K/Akt, and JNK/ERK MAP kinase pathways (Sieg et al., 2000; Moreno-Layseca 
and Streuli, 2014). 
 
Integrin signalling has a number of functions including the influence of the fate of 
cells, particularly anchorage dependent cells (where viability is controlled by 
adhesions, by interactions with the ECM). Changes in integrin interaction can lead 
to mitogenic (growth) signalling or apoptotic signalling (Danen and Yamada, 2001; 
Stupack and Cheresh, 2002). 
 
Integrins can affect the growth and motility of cells by their interactions with growth 
factor signalling pathways. This occurs in a number of ways, first by trans-activation 
of growth factor receptors, and second by the influence of components of growth 
factor signalling pathways. It has been suggested that growth factor receptors can 
cluster with integrins with FAK acting as a “receptor-proximal bridging protein” (Sieg 
et al., 2000). This is thought to lead to phosphorylation affecting a number of growth 
factor pathways including PDGF, FGF, HGF and EGF (Schwartz and Ginsberg, 
2002). There is also a lot of crossover between pathways downstream of integrins 
and growth factor receptors. A number of integrin signals are involved in proliferative 
signalling but the ERK and AKT pathways in particular plays a role in cell cycle 
control. The activation of these proteins by adhesion pathways contribute to cyclin 
D1 production allowing cells to proceed from G1 to S phase (Moreno-Layseca and 
Streuli, 2014). This is just one example of how anchorage via integrins mediates 
progression through the cell cycle. 
 
It has also been suggested that in the absence of a ligand integrins can cause cells 
to enter apoptosis. There are two distinct mechanisms that integrin blockade can be 
a part of, anoikis and Integrin Mediated Death (IMD). Anoikis is a form of apoptosis 
cause by detachment of the cell from the ECM. As adhesion receptors integrins play 
a role in this process and a number of signalling pathways related to integrins have 
been implicated in this process such as the PI3K pathway (Frisch and Screaton, 
2001). It has been shown in vitro, that blockade of αvβ5 and αvβ3 can lead to anoikis 
in endothelial cells (Maubant et al., 2006). On the other hand, the second 
mechanism of apoptosis, IMD, is proposed to be caused directly by unligated 
integrins. In this process caspase-8 is recruited and activated giving integrins a 
direct role in cell survival (Stupack et al., 2001). 
 
Overall integrin signalling plays role in wide a number of cell processes that dictate 
cell fate. The specific functions, however, of each of the members of this protein 
family is determined by the localisation and ligand binding affinity of each integrin 
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(Takada et al., 2007). As integrins are expressed in most tissues they have function 
in many processes, both homeostatic and pathological. 
 
1.3.4 Integrins and Cancer 
 
One pathological process that many members of the integrin family have been 
shown to have a role in is cancer. These functions have been shown to be highly 
complex, playing parts in a number of the hallmarks of carcinogenesis including 
metastasis, angiogenesis, and cell proliferation. A number of integrins are 
expressed by cells in the immune system giving this protein family links to the 
relationship between cancer and the immune system. There are also changes to the 
expression of integrins within cancer cells themselves. Some integrins are up-
regulated, αvβ3, while some, such as the potential tumour suppressor α2β1, are 
downregulated by cancer cells (Desgrosellier and Cheresh, 2010).  
 
Those members of the integrin family upregulated by cancer cells have been shown 
to be linked with a more invasive and metastatic phenotype (Keely, et al., 1998). 
This is conferred by a number of factors including the signalling pathways and 
adhesive properties mentioned above. The anchorage related signalling pathways 
that control both growth and survival play important roles in the proliferative potential 
of tumour cells (Liotta and Kohn, 2001). Through these integrins can control the 
growth of tumour playing anti-tumorigenic roles that must be overcome. While 
integrins can convey signals that encourage cell survival when ligated, when they 
have no ligand their signalling can lead to cells entering apoptosis pathways 
(Desgrosellier and Cheresh, 2010). As well as survival signals, when connected to 
stromal components they encourage the progression of cells through the cell cycle 
through their coupling to growth factor receptors. In tumour cells this dependence 
on the adhesion for cell cycle progression diminishes their proliferative potential. 
One example of this is α5β1 which in the absence of its fibronectin substrate 
diminishes proliferation of tumour cell lines leaving them unable to progress to S 
phase of the cell cycle (Varner and Cheresh, 1996). Tumours must overcome these 
pathways before gaining the anchorage-independent growth that characterises 
them. 
 
The protein family also confers a number of tumour supportive properties however, 
in some cases enhancing oncogenic signalling, and integrin adhesion to the ECM 
can facilitate a more aggressive cancer phenotype by supporting invasion and 
migration. The focal adhesion complexes that integrin clustering is part of can 
facilitate the metastasis of tumour cells in a number of ways. First integrins can 
support invasion of tissues at the site of the primary tumour and at metastatic sites 
by their adherence properties (Hood and Cheresh, 2002). Second, integrins play 
important roles in cell migration through their links to the actin cytoskeleton 
supporting the formation of stress fibres. This then supports the migration of integrin 
expressing cancer cells to and from tissues to transport systems in metastasis 
(Keely et al., 1998; Jin and Varner, 2004).  
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Figure 7: The invasive and migrational roles of integrins based on their 
attachments between the cell and the extracellular matrix (Margadant et al., 
2013) 
 
Integrins expression in cancer biology is not just confined to the tumour cells 
themselves, but also extends to cells in the tumour niche including bone-marrow 
derived cells and endothelial cells. Integrins expressed by immune cells play a 
number of roles. They can play important roles in the trafficking of leukocytes to 
tumours by facilitating the adhesion of these cells to the endothelium. One example 
of this is α4β1 which regulates tumour invasion by myeloid cells and consequently 
the colonisation of the tumour by macrophages (Jin et al., 2006). Integrins on both 
tumour cells (αvβ3) and platelets (αIIbβ3) are also essential for the formation of 
bridges between these cell types increasing the chance of survival of metastatic 
cells in circulation and promoting tumour cell arrest (Felding-Habermann et al., 
2001; Desgrosellier and Cheresh, 2010).  
 
The expression of integrins by another tumour niche component, endothelial cells, 
has also been of particular interest in cancer research because of their support of 
angiogenesis. The integrins αvβ3 and αvβ5 are thought to play direct parts in 
angiogenesis supporting the migration, proliferation and survival of endothelial cells 
(Jin and Varner, 2004). These roles in increasing tumour angiogenesis have led to 
the study of these integrins as potential therapeutic targets. A second role comes 
from the regulation of endothelial cell interactions with pericytes by αvβ5. In tumours 
this interaction can be faulty leading to unstable vessels which are poor drug 
delivery systems (Desgrosellier and Cheresh, 2010).  
 
1.4 Integrin αvβ3  
 
1.4.1 Structure and Ligands of αvβ3 Integrin 
 
As with other integrins αvβ3 is a transmembrane protein that is conveys intracellular 
signals and interacts with the ECM via inside-out and outside-in signalling. This 
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integrin conforms to the switchblade model existing in three states that regulate the 
activity of integrins, the bent conformation, extended with closed headpiece and the 
ligand bound extended conformation.  
 
Discovering the crystalline structure of the integrin αvβ3 in the presence of Ca2+ and 
Mn2+ (Arnaout et al., 2002) was crucial in shedding light on the integrin structure and 
activation models described above. Of particular importance were studies looking 
at the interactions of αvβ3 integrin with a ligand. A critical part of the αvβ3 integrin 
structure is that instead of the αI domain it has the αI-like domain (Shimaoka and 
Springer, 2003; Puklin-Faucher and Sheetz, 2009).  This is an essential ligand 
binding domain, found on the β subunit, that interacts with the β propeller, present 
on the α subunit (Arnaout et al., 2002). When the ligand is bound it interacts 
extensively with these domains, and with the MIDAS motif found in the αI-like 
domain (Arnaout et al., 2007). This is facilitated by conformational changes in the 
high affinity conformation of αvβ3 where the MIDAS motif opens up allowing 
interactions with the ligand and the β propeller and αI-like domain move closer 
together (Arnaout et al., 2007; Shimaoka and Springer, 2003).  
 
During their bi-directional signalling the different integrins bind to a number of 
ligands. The ligand specificity is determined by integrin recognition sequences which 
in the case of αvβ3 is the RGD integrin binding site. This is a sequence of three 
amino acids; Arg-Gly-Asp which is expressed by ligands and recognised by the 
ligand binding site of αvβ3 integrin (Schaffner and Dard, 2003). The RGD motif 
interacts with αvβ3 integrin in a number of ways. The divalent cations in the MIDAS 
within the αI-like domain co-ordinate with the ligand aspartic acid (Shimaoka and 
Springer, 2003) and Asp218 of the β propeller on the αv subunit interacts with the 
arginine residue (Arnaout et al., 2002). 
 
A number of proteins express this RGD sequence including some ECM 
components. As such integrin αvβ3 binds to a number of ECM proteins including von 
Willebrand Factor, vitronectin, fibrinogen, collagen, fibronectin and osteopontin 
(Schaffner and Dard, 2003). In this context as with most integrins αvβ3 plays a role 
in focal adhesion complexes. There are also a number of ligands apart from matrix 
proteins including some membrane receptors (counter receptors) that contain the 
RGD sequence, facilitating cell-cell interactions. 
 
Apart from the β propeller on the α subunit there are three other domains that form 
the leg. The β subunit has six leg domains that are linked to the αI-like domain via 
a hybrid domain. These include four EGF domains linked by disulphide bonds and 
a β tail domain (βTD) (Arnaout et al., 2002; Arnaout et al., 2007). These β leg 
domains are important, particularly the βTD in intracellular integrin signalling 
supporting the formation of signalling complexes (including FAK and Src) and 
attachments to the actin cytoskeleton (Arnaout et al., 2002; Puklin-Faucher and 
Sheetz, 2009). When talin binds to the β subunit leg it can initiate inside-out integrin 
activation and signalling leading to tail dissociation and an increase in the angle 
between the hybrid domain and αI-like domain in a switchblade like movement 
(Puklin-Faucher and Sheetz, 2009; Shimaoka and Springer, 2003). Intracellular 
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binding of talin will also lead to integrin clustering, an important step in the formation 
of focal adhesions (Puklin-Faucher and Sheetz, 2009; Margadant et al., 2011).  
 
As with other integrins, these interactions control the survival, morphology, growth 
and in some cases differentiation of cells.  
 
1.4.2 Signalling of αvβ3 Integrin in Endothelial Cells 
 
The main functions of the endothelial cells are as a transport system and barrier. 
This plays roles in the migration of cells from one organ to another and the formation 
of new blood vessels. Studying the cell specific roles of proteins has been an 
essential part of dissecting the functions of proteins in homeostasis in disease. This 
is because of the importance of location and time of expression when painting a 
picture of the function of proteins. The integrin αvβ3 is expressed by a number of cell 
types including smooth muscle cells, monocytes, platelets and endothelial cells 
(Shimaoka and Springer, 2003). Its role in endothelial cells in particular has been 
studied because of the highly complex part it plays in tumour angiogenesis. This in 
turn has led to its study as a therapeutic target. 
 
Signalling of αvβ3 integrin can affect the behaviour of endothelial cells. As described 
above, integrins can cluster with growth factor receptors and crosstalk with their 
pathways. In endothelial cells one important example is the co-operation between 
αvβ3 and VEGFR-2. This controls adhesive and migratory properties of endothelial 
cells in specific scenarios including VEGF induced angiogenesis (Weiss and 
Cheresh, 2011). The receptor complexes that these two transmembrane proteins 
form have been shown by co-immunoprecipitation (Soldi et al., 1999). The 
importance of this complex has also been shown as disrupting it via cytoplasmic 
mutation of the β3 subunit will abrogate the migration and adhesion of endothelial 
cells (Plow et al., 2014). This collaboration is particularly evident when αvβ3 is 
interacting with its receptor vitronectin bringing about an increase in VEGFR2 
phosphorylation and its signalling response. This in turn leads to an increase in 
endothelial cell migration and proliferation (Soldi et al., 1999). This example of inside 
out signalling is dependent upon kindlin-2 binding to the β3 cytoplasmic tail via the 
amino acids Arg-Gly-Thr (Liao et al., 2015). It causes the activation of VEGFR-2 
signalling pathway including FAK, which enables motility and proliferation and 
RasMAPK which is linked to proliferation (Munoz-Chapuli et al., 2004; Karkkainen 
and Petrova, 2000).  
 
There are also some αvβ3 signalling pathways, which can govern the survival and 
proliferation of endothelial cells. These are also commonly linked to the interactions 
that αvβ3 facilitates with the ECM. First, there is evidence that αvβ3 induces survival 
by suppressing the apoptotic protein p53 and one of the products it induces, the cell 
cycle inhibitor p21WAF1/CIP1 (Strömblad et al., 1996). Second the integrin can 
enhance survival by increasing the expression of the anti-apoptotic protein Bcl-2 in 
comparison to Bax (Munoz-Chapuli et al., 2004; Soldi et al., 1999).  These roles 
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have been supported by evidence that antagonists of αvβ3 integrin lead to an 
increase in apoptosis of endothelial cells (Soldi et al., 1999).  
 
Conversely, it has been suggested that when αvβ3 integrin is unligated its signalling 
can lead to apoptosis in endothelial cells in two main ways. One theory is based on 
evidence that the apoptotic protein caspase-8 interacts directly with the cytoplasmic 
domain of the β3 subunit. It is suggested that when αvβ3 integrin interacts with an 
extracellular ligand, caspase-8 remains bound and active but when the integrin is 
unbound caspase-8 is activated allowing it to induce apoptosis (Sheppard, 2004; 
Stupack et al., 2001). The second theory also suggests that unligated αvβ3 will lead 
to the activation of caspase-8 but this time through another pathway. When the 
integrin is unligated protein Kinase A is activated, a process shown to be 
suppressed when αvβ3 interacts with ligands. When this apoptotic pathway is 
activated the angiogenic process is disrupted showing the importance of integrin 
adhesion in the formation of new blood vessels (Kim et al., 2002).  
 
Most research into αvβ3 functions in endothelial cells has focused on how it affects 
cell behaviour. There is also some evidence however that αvβ3 might play a role in 
trans-endothelial migration. One example is evidence that expression of αvβ3 by 
endothelial cells can facilitate platelet adhesion. It was shown that activating the 
endothelium increased αvβ3 expression and platelet adhesion and that addition of a 
cyclic peptide selective for αvβ3 disrupted this interaction (Gawaz et al., 1997).  
 
Overall studies of these functions have led to suggestions that αvβ3 has a role in the 
remodelling of the vasculature supporting an angiogenic phenotype in endothelial 
cells. This is a complex role, however, that depends on the substrate and the cellular 
context of expression. To study these roles in detail a number of endothelial cell 
specific αvβ3 integrin knockout mouse models have been created. One of these is 
harnessed in this study, the Tie-1Cre mouse model which knocks out the β3 subunit 
and confines Cre recombinase activity to endothelial cells using the Tie-1 promoter 
(Gustafsson et al., 2001). This is just one example of models available to study αvβ3 
in endothelial cells. 
 
1.4.3 The Role of αvβ3 Integrin in Cancer 
 
The integrin αvβ3 has a number of roles supporting tumour progression. Apart from 
its role in angiogenesis it can also be involved in migration of immune cells. It is also 
known to be highly expressed in a number of cancers and, via its interactions with 
the extracellular matrix, αvβ3 supports invasion. This has been linked in multiple 
studies to a poor prognosis, supporting the metastatic properties of cancer cells. In 
an aging population great importance has been placed on finding therapeutic targets 
for anti-cancer therapies and αvβ3 is one example.  
 
As described in section 1.1.3 the migration of endothelial cells and their eventual 
proliferation is essential for sprouting angiogenesis. The role of αvβ3 integrin in these 
processes, and in endothelial survival has led to suggestions of a role for this integrin 
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in angiogenesis. This has been supported by evidence that αvβ3 is upregulated by 
angiogenic endothelium (Munoz-Chapuli et al., 2004; Sheppard, 2004). The 
expression of this integrin can also be induced by pro-angiogenic factors (Jahroudi 
and Greenberger, 1995). One example is Del-1 which can induce pro-angiogenic 
gene transcription when bound to αvβ5 integrin. This will induce the expression of 
the angiogenic transcription factor Hox-D3 transcription factor which in turn 
increases the expression of αvβ3 (Sheppard, 2004).  
 
The importance of this process in tumour progression has led to studies looking at 
αvβ3 specifically in relation to tumour angiogenesis. The interactions of this integrin 
with VEGFR-2 control the activation of these receptors with cross talk dependent on 
Src. This increases VEGF-A induced angiogenesis which is particularly prevalent in 
the tumour (Weiss and Cheresh, 2011). This pro-angiogenic role in the tumour is 
supported by studies that look at the effect of αvβ3 antagonists on angiogenesis. 
One example is the use of cilengitide, a cyclic RGD peptide, in tumours which can 
decrease blood vessel growth and increase endothelial cell apoptosis further 
proving the angiogenic properties of αvβ3 (Liu et al., 2008; Weiss and Cheresh, 
2011).  
 
The role that αvβ3 plays in angiogenesis is highly complex however which is evident 
from studies using β3 knock out mice. Studying mice deficient in the β3 subunit led 
to an unexpected increase in pathological angiogenesis in the mouse. This provided 
a pro-tumorigenic environment and led to enhanced tumour growth. Since there 
were also elevated levels of VEGFR-2 in these mice a compensation mechanism 
exists revolving around VEGFR-2 (Reynolds et al., 2002). This has shown a far 
more intricate function for αvβ3 in angiogenesis that would need to be dissected 
before αvβ3 antagonists could be used in clinical settings. 
 
Another major role that αvβ3 plays in tumorigenesis is down to its expression by 
cancer cells themselves. This integrin can be upregulated by a number of cancers 
including glioblastomas and breast cancers (Weiss and Cheresh, 2011). This 
increase in expression leads to an advantage in metastasis supporting the migration 
and invasion of cancer cells. In the case of breast cancer, it is also proposed to 
support homing to the bone because of its ability to recognise specific components 
of the bone ECM such as bone sialoprotein (Sloan and Anderson, 2002). It is 
recruited to the migrating edge of cells in a process shown in Figure 1.7 supporting 
movement along the ECM (Margadant et al., 2013). After migration αvβ3 plays a role 
in the formation of another set of specialised actin protrusions that govern invasion, 
invadopodia (Huttenlocher and Horwitz, 2011), also shown in Figure 1.7. In fact, the 
expression of αvβ3 has been shown to be linked to a trans-endothelial migratory 
phenotype which can be blocked with αvβ3 antibodies (Bauer et al., 2007).  
 
This integrin can also support tumour growth through a cancer cell specific role in a 
population of cancer cells which I have not yet discussed - cancer stem cells. These 
are a population of cells within the tumour that self-renew, differentiate and due to 
these characteristics have the potential to form tumours when transplanted. By 
eliminating this population of cells it is thought that the chance of tumour recurrence 
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in patients would decrease but this has not yet led to viable therapeutic options (Yu 
et al., 2012). The integrin αvβ3 is thought to have some influence in this 
subpopulation as β3 expression can be a marker of this population (Desgrosellier 
and Cheresh, 2010). This role has been studied leading to contradictory results. 
One paper showed that αvβ3 activates stem-like properties including anchorage 
independence, and tumour initiative potential by complexing with KRAS and RalB 
to activate TBK1/NFκB (Seguin et al., 2014). On the other hand, it has been 
suggested that when bound to vitronectin αvβ3 will lead to the downregulation of 
stem cell genes and nuclear localisation of β-catenin. They suggest that through this 
ligation cancer stem cells differentiate allowing the formation of new tumours; 
blocking the interaction between vitronectin and αvβ3 blocks tumour formation (Hurt 
et al., 2010). Whatever the function that αvβ3 plays in cancer stem cells, it further 
supports the direct role that αvβ3 performs in cancer biology.   
 
Overall the evidence shows that αvβ3 can be involved in supporting cancer 
progression in a number of ways.  
 
1.5.2 Previous Data 
 
As described previously, although αvβ3 has shown promise as a potential 
therapeutic target, when used in clinical trials, αvβ3 therapies have led to 
indeterminate results. To dissect the multifaceted role of proteins with extensive and 
complex roles, cell and tissue specific knockout mouse models can be exploited.  
 
It has been mentioned that the role of αvβ3 in endothelial cells has been a focus of 
research in this laboratory. Steri et al., 2014, carried out a number of studies looking 
at the role endothelial αvβ3 plays in the primary tumour using cell-specific knock out 
mice. It was shown that acute depletion of endothelial β3 integrin inhibits tumour 
growth and angiogenesis. 
 
There is a role for tumoural αvβ3 supported by clinical evidence correlating the 
expression of αvβ3 by tumours with a worse prognosis (Sloan et al., 2016). With a 
role in the primary tumour established the study was extended to examine the effect 
of depleting endothelial β3 integrin on the formation of secondary tumours.  
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Figure 8: Constitutive knock-out of β3 integrin in endothelial cells decreases 
lung metastasis  
(A) 1x106 CMT19TF1 cells were injected subcutaneously into β3flox/flox/Tie1 
Cre and WT (Cre-negative) mice and a primary tumour was grown for 2 weeks. 
The tumour was resected and the mice were then left for another 3 weeks to allow 
macrometastases to develop (B) Microscope images from H&E staining of lungs 
for the identification of tumour metastasis (C) The number of metastases on the 
stained sections were then counted (n=3 for each genotype, Mean + SEM from 3 
independent experiments, * p<0.05) 
 
A long term cell specific knock out mouse model of β3 depletion in endothelial cells 
was used, the β3 flox/flox/Tie1-Cre mouse model. In metastasis the primary tumour 
plays a very important role in allowing the secondary tumour to seed and develop 
at its metastatic site. As such the primary tumour was set up in a metastatic model 
shown in Figure 1.8A using CMT19TF1 cell line, a lung carcinoma cell line that 
spontaneously metastasises to the lung when grown subcutaneously (Steri, 2015). 
This model of spontaneous metastasis has been exploited and adapted throughout 
this study. Steri also performed experimental metastasis studies (performing tail 
vein injections of tumour cells, eliminating the set-up of the primary tumour) to 
compare with these results. This showed no difference in the number of metastasis 
in lungs β3 flox/flox/Tie1-Cre and Control mice. This shows that the primary tumour 
is essential in the metastatic advantage that αvβ3 confers.  
 
The primary tumour was grown to 1cm3, according to the restrictions of the Home 
Office Licence, before it was resected. The mice were then left for another three 
weeks to allow metastatic tumours to grow before being sacrificed. Paraffin sections 
from lungs were used for H&E staining to visualise metastases, shown in Figure 
1.8B. The number of metastatic tumours per section were then counted and the 
Injection of 1x10
6
 tumour cells 
2 weeks 
Resect 
3 weeks 
(A) 
(B) (C) 
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results of this are presented in Figure 1.8C. The experiment shows a decreased 
number of spontaneous lung metastases in endothelial β3 depleted animals 
compared to controls, showing that when αvβ3 integrin is depleted long term in 
endothelial cells there is a less supportive environment for a successful metastasis 
to occur. 
  
1.6 Project Aims  
 
The experiments presented in Figure 1.8 establish a pro-metastatic role for αvβ3 in 
endothelial cells. As described above endothelial cells can have a number of roles 
in cancer; they are a barrier for tumour cells and immune cells during metastasis, 
they can release a number of factors that support tumour growth and they play a 
part in the angiogenic switch. This and the importance of the primary tumour in this 
metastatic advantage were taken into account to decide on two main points of focus 
for the project. 
 
The aim of this project was to evaluate two options in relation to αvβ3 and its effect 
on metastasis: 
1. That the primary tumour vasculature might be “leaky”; have increased 
permeability leading to an increased number of circulating tumour cells  
2. That there may be changes in the pre-metastatic niche meaning αvβ3 may play 
a role in developing an environment more hospitable for metastatic tumour 
growth. 
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2. Method 
 
2.1 In vitro Cell Lines and Growth 
2.1. CMT19T F1 
This cell line was based on the mouse lung carcinoma CMT19T cell line derived 
from the CMT167 cell line. These cells were selected after one round of 
spontaneous metastasis to increase their metastatic potential to the lung. 
2.1.2 B6-LV1 
This was a breast carcinoma cell line given by the Weilbaecher lab which 
spontaneously metastasis to bone and lung obtained through multiple rounds of in 
vivo metastatic selection. 
2.1.3 Maintenance of Cell Culture 
Cells were grown in DMEM high glucose media at 37°C in a 5% CO2 humidified 
atmosphere in gelatine coated flasks. Cells were maintained through passaging 
when they reached  ̴ 80% confluency washing with x1 PBS and 0.25% 
Trypsin:EDTA to detach cells.  
2.1.4 Preparation for Injection 
At  ̴ 80% confluency cells were detached with 0.25% Trypsin:EDTA and collected in 
falcon tubes for counting. Following this cells were centrifuged at 1200 x g for 15 
minutes before the supernatant was removed and the cells were washed in PBS. 
CMT19T F1 cells were then resuspended in PBS to allow injections of 1x106 
cells/100µl and kept on ice before use. B6-LV1 cells were then resuspended in 1:1 
Matrigel/PBS mixture to allow injections of 1x106/50µl.  
 
2.2 Cre Genotyping 
2.2.1 Isolation of DNA from Tissues 
Tissue from the ear or tail was digested in 100µl tail lysis buffer overnight at 56°C. 
Then 100µl of isopropanol was added to each sample to precipitate the DNA and 
the samples were centrifuged at 2500 x g for 20 minutes. The pellet was dried for 
30 minutes at 56°C, resuspended in 200µl TE Buffer and left at RT overnight.  
2.2.2 PCR 
Each PCR sample contained 9.1µl of MegaMix Blue Reagent, 0.08µl of forward 
primer and 0.08µl of reverse primer (both at 100 µM starting concentration), and 
0.8µl isolated DNA. These went through the following reaction 95°C for 4 minutes 
followed by 35 cycles of denaturation (95°C for 1 minute), annealing (57.5°C for 45 
seconds) and extension (72°C for 1 minute). The programme finished with an 
elongation step at 72°C for 10 minutes.  
2.2.3 Electrophoresis 
A 1.8% agarose gel (1.8g agarose, 98ml dH2O, 2ml 50x TAE Buffer, 5µl 10mg/ml 
Ethidium Bromide) was used for DNA electrophoresis. Amplified DNA samples were 
loaded with 1x Loading Dye and a 1Kb DNA Ladder and separated for about 1 hour 
at 100V. The gel was then imaged under UV light using a UV Gel Image Capture 
System Box.  
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2.3 In vivo Studies 
2.3.1 Injections 
Mice aged between 6-8 weeks were immobilised and injected subcutaneously 
(CMT19T F1) or into the mammary fat pad (B6-LV1) with cells prepared as 
described.  
2.3.2 Tumour Resection 
The tumour size was measure regularly via callipers until it reached 1cm3, at about 
week 3. At this point mice were anaesthetised with isoflurane inhalant and the 
tumour was surgically resected. 
2.3.3 Primary Tumour Permeability Assay 
B6-LV1 Tumours were grown for 14 days. Tail vein injections of 200µl 1% FITC-
dextran (x1 PBS) were performed.  After 30 minutes, animals were perfused with 
PBS and the primary tumours were harvested. They were placed in formamide at 
37°C for 48 hours and 200µl of this solution was analysed by fluorescence 
(excitation 490nm and emission 520nm). Obtained OD values were normalised 
against the weight of the tumour.  
2.3.4 Sacrifice and Dissection 
Mice were euthanised by cervical dislocation and lungs were inflated by tracheal 
injection and removed sterilely for later analysis. 
 
2.4 Immunohistochemical Analysis 
2.4.1 Embedding 
Lungs were inflated with 5% gelatin extracted and fixed in 4% PFA for 1 hour at 4°C 
followed by 20% sucrose overnight at 4°C. The lungs were then embedded in 7.5% 
gelatin:15% sucrose. Blocks were then flash frozen in isopentane cooled by liquid 
nitrogen and stored at -80°C.  
2.4.2 Sectioning 
Sections of 10µm were taken at -20°C using a CryoStat (Leica Biotech) and stored 
at -80°C. 
2.4.3 Staining 
Sections were warmed in PBS to dissolve gelatin before blocking with 5% Goat 
Serum/0.1% Triton/PBS. The sections were then left for 30 minutes at RT in a moist 
chamber. The blocking solution was replaced with FITC-conjugated anti-CD45 
diluted 1/500 in 5% Goat Serum/PBS and left in a moist chamber overnight at 4°C. 
Slides were washed in 1x PBS for 5 minutes three times and mounted with 
Flouromount, containing DAPI.  
2.4.4 Microscopy 
A Zeiss AxioPlan 2ie Microscope was used to take a defined region (encompassing 
the lung) of 5x images of DAPI and CD45 staining with a 10% overlap that were 
stitched by AxioPlan software.  
 
2.4.5 Analysis 
A Macro on FIJI was used with the following method. The region of interest was 
defined using a freehand tool and a threshold value, Triangle, was set. to eliminate 
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any background and focus on the staining of interest. Finally, parameters were set 
to filter objects according to circularity and size. The values were normalised against 
the ROI size to gain comparable values. 
 
2.5 Flow Cytometry 
2.5.1 Sample Preparation 
Lung lobes were removed and rinsed in 70% ethanol and minced until 
homogeneous. This was digested with 0.1% Collagenase I/ PBS (supplemented 
with 1mM CaCl2/1mM MgCl2) at 37°C for 1 hour. A single cell suspension was then 
created by filtering cells through a 70µm mesh. These were collected in FACs tubes 
with 1ml red blood lysis buffer and incubated at RT for 1 minute. The cells were then 
centrifuged at 1000 x g for 5 minutes and resuspended in FACS buffer.  
2.5.2 Staining 
Samples were stained with four antibodies diluted 1:200 in FACS buffer; FITC anti-
CD45, PE anti-Ly6C, PerCP-Cy5.5 anti-Gr-1, and APC anti-CD11b and incubated 
on ice for 20 minutes. Samples were then washed twice in PBS, and resuspended 
in 2% PFA/PBS and stored at 4°C until acquisition. 
2.5.3 Acquisition 
Samples were run using a BD Accuri C6 flow cytometer collecting 1x107 events per 
sample. Single stained controls were also run to allow later compensation. 
2.5.4 Analysis 
Compensation was performed using single stained fluorescence controls to account 
for spill-over into other channels. An FSC-A/SSC-A plot was then used to remove 
cell debris and gate onto live cells. A quadrant plot was then used to gate onto the 
myeloid population (CD45+/CD11b) followed by a scatter plot to differentiate 
between PMN and Monocyte populations of MDSCs.  
 
2.6 Cytokine Array 
2.6.1 Sample Preparation 
Lung lobes were removed and homogenised in x1 PBS containing Halt Protease 
Inhibitor and Triton X-100 was added to a final concentration of 1%. Samples were 
then frozen at -80°C overnight after which they were thawed and centrifuged at for 
5 minutes at 1200 x g to remove cell debris. The protein content was then quantified 
via a Bio-Rad DC Protein Assay Kit using BSA standards of known concentrations. 
Then 5µl of each sample was added to 200µl Reagent B and 25µl (50:1 Reagent 
A:Reagent S) and incubated at RT for 15 minutes. Absorbance was then measured 
at 750nm and the standards were used to create a standard curve used to obtain 
protein concentrations for unknown samples. Samples were then pooled (7 of each 
tumour bearing genotype) to allow equal protein volume (57µg) from each samples 
up to 200µg. 
2.6.2 Immunoblotting 
An immunoblotting procedure was then followed with the reagents and according to 
the instructions supplied by the manufacturer of the kit.  
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2.6.3 Imaging and Analysis 
Blots were imaged using a FUJIFILM Luminescent Image Analyser LAS-1000plus 
for up to 10 minutes taking pictures at 30 second intervals. The densities of each 
spot was then analysed using FIJI analysing two lanes at once using one as a 
control to produce comparable values. An average of reference spots was then 
taken and values were normalised to these.  
 
2.7 Western Blot Analysis 
2.7.1 Sample Preparation 
Lungs were prepared and quantified as described in 2.6.1. Samples were prepared 
to allow 35µg of protein in 1x Reducing Buffer and 1x Sample Buffer with 0.1% 
Tween-20 x1 PBS up to 20µl. These were then incubated at 95°C for 5 minutes and 
centrifuged at 10000 x g for 1 minute.  
2.7.2 SDS-PAGE Electrophoresis 
Prepared samples were loaded into a 12% polyacrylamide gel with SpectraTM 
Multicolour Broad Range Protein Ladder. The gel was then run in Running Buffer at 
100V until samples reached the bottom of the gel.  
2.7.3 Transfer 
Protein was then transferred to a nitrocellulose membrane in Transfer Buffer at 4°C 
for 1 hour and 15 minutes at 115V. 
2.7.4 Immunoblotting 
The nitrocellulose membrane was blocked (5% Milk Protein in 0.1% Tween-20 PBS) 
for 30 minutes at RT and washed three times in 0.1% Tween-20 PBS for 5 minutes. 
The membrane was incubated with primary antibodies diluted 1:1000 (5% BSA in 
0.1% Tween-20 x1 PBS) overnight at 4°C. It was then washed three times in 0.1% 
Tween-20 PBS for 5 minutes. Secondary antibodies diluted 1:2000 (5% BSA in 
0.1% Tween-20 x1 PBS) were then added and the membrane was incubated for 1 
hour at RT. Finally, the membrane was washed three times in 0.1% Tween-20 x1 
PBS for 5 minutes. 
2.7.5 Imaging and Analysis 
The membrane was incubated for 1 minute with ECL reagents and imaged with a 
FUJIFILM Luminescent Image Analyser LAS-1000plus taking images at 20 second 
intervals. The image was then quantified with FIJI normalising results against a 
loading control. 
 
2.8 Statistical Analysis 
Data was analysed by Student's t-test and ANOVA using the GraphPad Prism 
v6.01. P values <0.05 were considered significant and error bars on graphs show 
mean +SEM.  
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2.9 Reagents, Buffers and Kits 
 
2.9.1 Buffers and Solutions 
DMEM High Glucose 
DMEM high glucose+Glutamax (Invitrogen), 10% Fetal bovine serum (FCS), heat 
inactivated (HyClone, Invitrogen), 2 mM L-Glutamine (Invitrogen), 100 U/ml 
Penicillin/ 100 µg/ml Streptomycin (Invitrogen) 
Tail Lysis Buffer 
0.2% SDS, 100 mM Tris-base, 200 mM NaCl, 5 mM EDTA, 0.5 mg/ml proteinase K 
TE Buffer 
10 mM Tris-base, 1 mM EDTA 
x50 TAE Buffer 
242 g Tris-base, 57.1ml acetate (100% acetic acid), 100 ml 0.5 M EDTA, up to 1 
litre dH2O 
 
FACS Buffer 
x1 PBS, 1% Fetal bovine serum, 10mM HEPES (1M stock solution, Invitrogen) 
12% Acrylamide Gel 
A) Stacking 
5% Acrylamide Solution (30%, Protogel, National Diagnostics (Hessle, UK)), 0.1% 
SDS, 0.1% ammonium persulphate, 0.5% TEMED, dH2O 
B) Resolving 
12% Acrylamide Solution, 0.1% SDS 3ml, 0.1% ammonium persulfate, 0.5% 
TEMED, dH2O 
Running buffer  
25 mM Tris-base, 192 mM glycine, 0.1% SDS, dH2O 
Transfer buffer  
25 mM Tris base, 192 mM glycine, 20% methanol, dH2O 
 
2.9.2 Reagents 
Matrigel (0.7% solution): BD Bioscience 
MegaMix Blue Reagent: Cambio (Cambridge, UK) 
FITC Dextran (low MW 4300): Sigma-Aldrich 
1Kb Plus DNA Ladder: Invitrogen 
Fluoromount-G with DAPI: eBioscience (Hatfield, UK) 
Red blood lysis buffer (10X): eBioscience (Hatfield, UK) 
Halt Protease Inhibitor: Invitrogen 
NuPAGE Sample Reducing Agent (10X): Invitrogen 
NuPAGE LDS Sample Buffer (4X): Invitrogen  
SpectraTM Multicolour Broad Range Protein Ladder: ThermoFisher Scientific (UK) 
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2.9.3 Kits 
Bio-Rad DC Protein Assay kit: Bio-Rad Laboratories (Hertfordshire, UK)  
Proteome Profiler Mouse XL Cytokine Array ARY028: R&D Systems (Abingdon, UK) 
ECL kit: Bio-Rad Laboratories (Hertfordshire, UK)  
 
2.9.4 Antibodies 
2.9.4.1 Flow Cytometry 
FITC anti-CD45 (Immunohistochemistry) – Clone A20: eBioscience (Hatfield, UK) 
PE anti-Ly6C – Clone HK1.4: eBioscience (Hatfield, UK) 
PerCP-Cy5.5 anti-Gr-1 – Clone M1/70: eBioscience (Hatfield, UK) 
APC anti-CD11b – Clone RB6-8C5: eBioscience (Hatfield, UK) 
2.9.4.2 Western Blot 
anti-GAPDH – 14C10, # 2118: Cell Signalling Technology 
anti-CCL21 – ab9903: abcam 
anti-CCL6 – ab196521: abcam 
anti-P-Selectin - # AF737: R&DSystems (Abingdon, UK) 
 
2.9.5 Primers 
Tie1-Cre PCR  
Forward primer: 5’-GCC TGC ATT ACC GGT CGA TGC AAC GA-3’  
Reverse primer: 5’-GTG GCA GAT GGC GCG GCA ACA CCA TT-3’ 
 
2.9.6 Equipment 
PROTRAN Nitrocellulose Membrane: ThermoFisher Scientific (UK) 
UV BioDoc-It Imaging System: UVP (Cambridge, UK) 
Accurie C6 flow cytometer: BD Bioscience 
FUJIFILM Luminescent Image Analyser LAS-1000plus: Fujifilm UK (Bedford, UK) 
UV/Vis Spectrometer Microplate Reader: BMG Labtech (Aylesbury, UK) 
Zeiss AxioPlan 2ie Microscope  
CryoStat (Leica Biotech) 
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3. Results 
 
3.1 Studying the Interactions of the Endothelium with Tumour Cells 
 
The first step of the metastatic cascade that endothelial cells play a role in is 
intravasation, where they act as a physical barrier between the tumour and a 
transport system. Changes to this barrier will affect the chance of cancer cells 
gaining access to a transport system. With a change to the number of cancer cells 
in the vascular system the chance of metastatic cells reaching a metastatic site and 
successfully colonising it increases (Criscuoli et al., 2005).  
 
There is evidence that FAK, a protein influenced by αvβ3, can affect the permeability 
of the vasculature by targeting vascular endothelial cadherin (Chen et al., 2012). 
Increasing the permeability of the vasculature influences the intravasation and 
extravasation of cancer and cancer supportive cells, consequently encouraging 
metastasis (Jean et al., 2014).  
 
To study the potential of αvβ3 integrin to influence permeability an in vivo study of 
the permeability of the primary tumour vasculature was carried out.  
Figure 1: The permeability of the tumour vasculature in vivo is not affected 
by knocking out αvβ3 in endothelial cells. 
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(A) B6LV1 tumours grown for 3 weeks in WT (Cre-negative) and 
β3flox/flox/Tie1-Cre (β3IntegrinΔEC) mice. FITC-dextran was injected 
intravenously and circulated for 30 minutes before sacrifice. Tumours were left 
for 48 hours in formamide to extract FITC and fluorescence was quantified. (B) 
The fluorescence was normalised against the tumour weight and the mean is 
shown in a bar graph (WT n=6, β3IntegrinΔEC n=5; Mean + SEM; ns= no 
significance). 
 
A breast cancer cell line (B6LV1) that spontaneously metastasises to breast and 
lung was used for this experiment, shown in Figure 3.1A. Tumours were grown for 
three weeks before mice were sacrificed for the experiment. Low molecular weight 
FITC-dextran, which is small enough to leak out of permeable vessels, was injected 
via the tail vein. The mice where left for 30 minutes for the FITC-dextran to circulate 
before the primary tumours were harvested. These were left in formamide for 48 
hours to extract the FITC-dextran before fluorescence was quantified. Results were 
then normalised against the weight of the primary tumour and are presented in 
Figure 3.1B. 
 
Figure 3.1B shows that αvβ3 has no significant effect on the permeability of the 
primary tumour vasculature. This was supported by studies from Steri (2015; 
unpublished) that looked at a potential increase in intravasation/dissemination and 
consequently metastasis by identifying the numbers of tumour cells. Previous 
experiments showed that the numbers of circulating tumour cells were not 
significantly affected by a knockout of β3 integrin in endothelial cells. 
 
3.2 Cytokine Profile of the Pre-Metastatic Niche 
 
The pre-metastatic niche is the set-up of an environment in distant organs that leads 
to preferential metastasis to said organ. The formation and development of this 
niche is reliant upon signals from the primary tumour. The importance of the primary 
tumour in the metastatic phenotype in endothelial β3 integrin knock out mice, shown 
in the previously described experiments, may be explained by a role for αvβ3 integrin 
in influencing the pre-metastatic niche. 
 
Since it is secreted factors and cells from the primary tumour and bone marrow that 
are the essential elements for establishing the pre-metastatic niche, transport 
systems play an important role in the set-up. As such, endothelial barriers will control 
the movement of niche components to ‘soil’ tissues. One of the ways that the pre-
metastatic niche is manipulated is by cytokine release.  For example, VEGF, which 
has a well-documented role in supporting the homing of bone marrow components 
to tissues is known to play a significant role in niche generation (Kaplan et al., 2005).  
Cytokine presence is then propagated by the immune cells that begin to colonise 
the pre-metastatic environment. 
 
To assess how the cytokine profile of the pre-metastatic niche is affected by acute 
depletion of endothelial β3 integrin a cytokine array was used. Tumours were grown 
in seven mice from each genotype, WT (Cre-negative) and β3 flox/flox/Tie-1Cre, for 
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three weeks to allow time for the pre-metastatic niche to be set up. Lungs from these 
mice and three control non-tumour bearing β3IntegrinΔEC mice were lysed, 
quantified, and pooled so that there were equal quantities of protein from the 
individual samples in each pool. They were then used for a cytokine array that 
detected 111 mouse cytokines. The array was analysed using FIJITM using one 
consistent line to get around the arbitrary assignment of units. The results of the 
arrays were then normalised against an average of the three reference spots.  
 
Each of the 111 cytokines detected by the array was researched, looking for 
potential roles in cancer development and the immune system. The relevant 
cytokines have been grouped into six categories and are presented in graphs in 
Figure 3.2 with explanations of their roles in tables below.  
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Figure 2: The effect of depleting endothelial cell αvβ3 on the cytokine profile 
of the lung pre-metastatic niche. 
Untreated lungs (Control) and pre-metastatic lungs from β3flox/flox/Tie1-Cre and 
WT (Cre-negative) mice with tumours that had been grown for three weeks were 
digested. The tissue lysates of the same genotype (Control n=3, WT n=7, 
β3IntegrinΔEC n=7) were pooled into one sample that was used in a cytokine 
array. The array was analysed relative to reference points using ImageJ. The 
results were then assembled into groups according to the different functions of the 
cytokines. (A)Angiogenic markers (B) Pre-metastatic niche markers (C) 
Leukocyte recruitment markers. Myeloid cells have an important role in the 
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development of the pre-metastatic nice; (D) Monocyte recruitment markers (E) 
Macrophage recruitment markers (F) Neutrophil recruitment markers. 
 
The angiogenic potential of an environment is defined by the balance of pro to anti-
angiogenic factors. A number of angiogenic factors, including angiostatin, 
angiopoietin 1 and VEGF are shown in Figure 3.2A and the roles of these factors 
are shown in Table 1. Of these cytokines, a few (both pro and anti angiogenic) are 
much more greatly expressed by WT mice (VEGF, endoglin and endostatin) with 
most being almost equally expressed by WT and β3IntegrinΔEC but lower in non-
tumour bearing mice. Overall the expression patterns of the cytokine array do not 
seem to suggest any particular shift to a pro or anti angiogenic phenotype. 
 
Table 1: Angiogenic factors in the pre-metastatic niche 
 Cytokine Function 
Promoting 
Factors 
VEGF 
(VEGF-A) 
First known as a vascular permeability factor this cytokine 
has been shown to be essential for the vascularisation of the 
tumour stimulating the proliferation, migration and survival of 
endothelial cells (Ferrara et al., 2003; Neufeld et al., 1999; 
Bergers et al., 2000). 
Angiopoietin 1 Influences angiogenesis via its interaction with Tie2 
promoting endothelial cell survival and in the later stages of 
vascular remodelling inhibiting vessel permeability and 
stabilising blood vessels (Suri et al., 1996; Kwak et al., 1999; 
Gavard et al., 2008).  
MMP-2,-9 These proteases break down the basement membrane 
facilitating the movement of endothelial cells and playing an 
important role in vascular remodelling (Carmeliet and Jain, 
2000; Zheng et al., 2006). MMP-9 in particular is important 
for tumour angiogenesis by its stimulation of VEGF secretion 
and when genetically ablated, angiogenesis is reduced 
(Bergers et al., 2000). 
CXCL-1 A tumour promoting chemokine secreted from tumour and 
endothelial cells, it promotes the influx of angiogenesis 
supporting neutrophils and supports endothelial cell motility 
and proliferation (Miyake et al., 2013; Scapini et al., 2004). 
Endoglin A marker of tumour vasculature, endoglin is expressed by 
proliferating endothelial cells and plays an important role in 
forming a mature and stable vasculature in mice (Dallas et 
al., 2008; Ten Dijke et al., 2008. 
Inhibitory 
Factors 
CXCL-9,-10,-11 The production of these angiostatic cytokines is linked with 
a reduction in tumour angiogenesis (Liu et al., 2011). In vitro 
this effect has been shown to be mediated by the expression 
of the receptor CXCR3B on the endothelium (Strieter et al., 
2006) 
Endostatin An endogenous inhibitor of angiogenesis and anti-
tumorigenic cytokine, endostatin inhibits the migration and 
promotes apoptosis of endothelial cells (Dhanabal et al., 
1999; Yamaguchi et al., 1999; O’Reilly et al., 1997). 
 
There are a number of cytokines which have been studied as pre-metastatic niche 
related or metastasis supportive cytokines that were a part of this cytokine array. 
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These are presented in Figure 3.2B and more in depth descriptions of their roles are 
described in Table 2. 
 
While there mostly seems to be a trend towards an increase in expression of these 
cytokines in tumour bearing mice only a few show notable differences in expression 
in WT compared to β3IntegrinΔEC. The almost doubled expression of VEGF in 
tumour bearing WT mice, combined with its role in the formation of pre-metastatic 
cluster of haematopoietic progenitor cells (Kaplan et al., 2005) makes VEGF of 
interest. As does the particularly high expression and tumour cell homing role of 
CCL21 (Krieg and Boyman, 2009).  
 
Table 2: The functions of cytokines related to metastasis  
Cytokine Function 
VEGF This factor is secreted by the primary tumour and recruits VEGFR1+ HPCs to 
tissues. These form cellular clusters critical to pre-metastatic niche formation 
(Kaplan et al., 2005). 
MMP-9 When VEGFR1+ HPCs enter a tissue and from pre-metastatic clusters they 
secrete MMP-9. This contributes to pre-metastatic niche formation by 
degrading the basement membrane and allowing the invasion of further cells 
which define the niche (Kaplan et al., 2005; Kaplan et al., 2006). 
MMP-2 This is another protease secreted by BMDCs that are recruited to the pre-
metastatic niche (Sceneay et al., 2013). 
CCL21 The receptor for this chemokine, CCR7, is highly expressed by metastatic 
breast cancers and mediates the homing of these metastatic tumour cells to 
specific tissues (Strieter, 2001). 
DPPIV Expressed on the lung endothelium, DPPIV has been shown in vivo to 
facilitate the invasion of metastatic breast cancer cells by acting as an 
adhesion receptor in the lung (Johnson et al., 1993; Cheng et al., 1998). 
 
 
Cytokines and chemokines play important roles in the immune system, co-ordinating 
the homing of leukocytic populations to different tissues. Some are involved in the 
movement of specific leukocyte sub-populations but others control general 
leukocyte movement and the expression of these is grouped into Figure 3.2C. Most 
of the proteins below are involved in the extravasation of circulating leukocytes to 
peripheral tissues. They are not cytokines themselves, but their expression is 
influenced by surrounding cytokines.  
 
In Figure 3.2C there seems to be a correlation between depleting β3 integrin in 
endothelial cells and decreasing the expression of these leukocyte recruitment 
proteins. Since many of these proteins facilitate adhesion to the endothelium (as 
described in Table 3) and are expressed by endothelial cells these changes in 
expression in β3IntegrinΔEC mice is of particular interest. 
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Table 3: The leukocyte related functions of cytokines 
Cytokine Function 
P-Selectin This transmembrane protein is expressed by endothelial cells and plays a part in 
the trafficking of leukocytes to sites of inflammation (Muller, 2013). This role is 
facilitated by P-selectin’s interactions with selectin ligands on leukocytes such as 
P-selectin glycoprotein ligand-1 (Norman et al., 1995). The importance of this 
function has been shown in P-selectin knock out mice which display faulty 
leukocyte rolling and transendothelial migration (Mayadas et al., 1993).  
VCAM-1 Another protein that supports adhesion of leukocyte populations to the endothelial 
layer, it interacts with the leukocyte integrin VLA-4 allowing the tethering and rolling 
of leukocytes across the endothelium (Elices et al., 1990). 
ICAM-1 The presence of ICAM-1 is upregulated on the endothelium by pro-inflammatory 
cytokines (Lawson and Wolf, 2009). It interacts with LFA-1 on all leukocyte 
populations to support the adhesion and eventual migration of leukocytes to 
inflamed tissues (Makgoba et al., 1988). 
GAS-6 It plays a role in the sequestering and extravasation of leukocytes and when 
knocked out in mice the influx of leukocytes to sites of inflammation decreases 
(Tjwa et al., 2008; Laurance et al., 2012). 
 
The protein expression shown in Figure 3.2C may suggest an increased influx of 
leukocytes to the pre-metastatic niche in WT (Cre negative) mice. A number of the 
cytokines in the array control the movement of specific populations of immune cells 
that have tumour supportive roles. Some of these are described in Figures 3.2D-F.  
 
The recruitment of monocytes from the circulatory system to the primary tumour is 
a recognised part of tumour biology. Part of the myeloid lineage, they are pre-
cursors to a number of populations including macrophages and monocyte-derived 
dendritic cells (Richards et al., 2013). The presence of these cells has also been 
used to identify the existence of a pre-metastatic niche (Batista et al., 2014).  
 
The roles of all the cytokines associated with monocytes are described in Table 4 
but the cytokine of particular interest in Figure 3.2D is CCL2. The chemokine is one 
of the most well-known monocyte recruitment proteins. It plays an important role in 
the infiltration of monocytes into the primary tumour and via monocytes, will support 
the extravasation of tumour cells at metastatic sites (Bonapace et al., 2014; Qian et 
al., 2011). Despite this obviously pro-tumorigenic role, when β3 Integrin is depleted 
in endothelial cells and metastasis reduces, its expression increases.  
 
Table 4: Cytokines related to monocyte homing  
Cytokine Function 
CCL2 Chemokine for monocytes which expresses CCR2, the CCL2 receptor. In CCL2 
deficient mice monocyte recruitment to inflamed tissue is diminished (Qian et al., 
2011). 
CCL5  This is another potent monocyte chemokine via the CCR5 receptor and when this 
axis is disrupted monocyte infiltration decreases (Soria and Ben-Baruch, 2005). 
C5a Complement component 5a acts as a chemotactic agent for monocytes and upon 
binding its receptor C5L2, stimulates the release of cytokines (Manthey et al., 
2009). 
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GM-CSF Administering this to humans has been shown to increase the number of 
monocytes in circulation (Hamilton, 2002). 
CD14 This is a monocyte membrane bound protein that can be used as a marker for the 
presence of monocytes (Schütt, 1999; Simmons et al., 1989). 
CX3CL1 Expressed by endothelial cells CX3CL1 interacts with CX3CR1 on monocytes 
facilitating their adhesion to the endothelium as part of an inflammatory response. 
In secreted from it will also act as a monocytic chemokine (Imaizumi et al., 2004; 
Ancuta et al., 2006; Imaizumi et al., 2000). 
 
Part of the significance of monocytes in cancer biology is that they are pre-cursors 
to the macrophage lineage. After monocytes are recruited from circulation they will 
differentiate into macrophages. This differentiation is controlled by a range of 
cytokines including a number of those described in Table 5. Macrophages can have 
distinct roles in inflammation which is controlled by their polarisation to M1 (pro-
inflammatory) or M2 (anti-inflammatory) phenotypes. In tumours macrophages tend 
to shift to a tumour associated, M2c phenotype (Sica et al., 2006).  One cytokine 
that is presented in Figure 3.2E and plays an important role in this process in IL-10. 
Its expression pattern, however, does not suggest that it plays a role in the 
endothelial β3 integrin mediated metastatic phenotype.  
 
Mostly the expression of these macrophage associated cytokines in Figure 3.2E is 
low but CCL2 and CCL6 have interesting expression patterns in conflict with their 
published roles. Due to the monocytic recruitment properties of CCL2 it also 
correlates with the number of macrophages. Once again it reportedly plays a tumour 
and metastasis supportive role which stands at odds with its expression only in the 
lungs of tumour bearing β3IntegrinΔEC mice. This oddity is shared by CCL6 which 
has a role in macrophage homing and is also most strongly expressed by tumour 
bearing β3IntegrinΔEC mice.  
 
Table 5: Cytokines that regulate macrophage infiltration and function 
Cytokine Function 
M-CSF In a tumorigenic environment M-CSF can recruit macrophages, supporting their 
migration and survival (Mantovani et al., 2002). It can also stimulate the 
differentiation of monocytes to macrophages (Martinez et al., 2006). 
IL-10 This interleukin plays an important part in macrophage polarisation, supporting 
an M2c phenotype. These are known as tumour associated macrophages 
(Mantovani et al., 2005; Martinez et al., 2008). 
CCL2 In vivo CCL2 can act as a macrophage chemokine via the receptor CCR2. In 
tumour the levels of CCL2 positively correlate with the number of TAMs (Conti 
and Rollins, 2004; Zhang et al., 2010). 
CX3CL1 It has been shown in vitro and in vivo that CX3CL1 can recruit CX3CR1 
expressing macrophages (Reed et al., 2012; Truman et al., 2008). 
CCL6 Produced by a number of tumours it is most commonly a chemokine that 
facilitates homing of macrophages, an ability shown in vitro and in vivo (Coelho 
et al., 2007). 
 
 
 
 
Hannah Louise Chenoweth 
 
54 
 
 
Neutrophils are another subset of leukocyte with both pro-tumorigenic and anti-
tumorigenic properties in the primary tumour microenvironment in a similar way to 
polarised macrophages and T cells (Gregory and Houton, 2011). As part of the 
polymorphonuclear leukocyte (PMN) family, they have been described as 
determinants of a pre-metastatic soil (Batista et al., 2014).  
 
Of the neutrophil chemoattractants described in Table 6 CXCL5 was expressed 
most strongly with a trend suggesting that β3 integrin in endothelial cells could 
support the influx of neutrophils. Contrary to this both CCl-2 and -3, which are 
involved in the recruitment of PMN cells to tissues, are expressed by tumour bearing 
β3IntegrinΔEC mice but not by other mice. This recruitment of BMDCs is thought to 
support tumour growth so this expression pattern does not adhere to expectation. 
This could suggest a complex profile of PMNs with a different function in the pre-
metastatic niche of the different genotypes.  
 
However, with these chemoattractants not influencing the infiltration of just one 
population of immune cells it is hard to picture how these expression patterns might 
affect immune cells in the pre-metastatic niche. 
 
Table 6: Cytokines controlling PMN and Neutrophil infiltration 
Cytokine Function 
Myeloperoxidase* As a recruiter of neutrophils myeloperoxidase supports the adherence of 
these leukocytes to the wall of the endothelium eventually leading to tissue 
invasion (Klinke et al., 2011). 
CXCL-1,-2* Macrophages secrete these CXCR2 ligands, and they are critical in 
mediating the recruitment of neutrophils to tissues (De Filippo et al., 2013; 
Scapini et al., 2004). 
CXCL-5 Similarly to CXCL-1 and -2, CXCL-5 is a chemoattractant for neutrophils 
via the receptor CXCR-2. This effect has been demonstrated both in vitro 
and in vivo (Song et al., 2013; Vieira et al., 2009). 
CCL-2,-3* These are important mediators of neutrophil recruitment, promoting their 
extravasation into tissues and when depleted neutrophil transmigration 
decreases (Reichel et al., 2012; Reichel et al., 2009). 
C5a Exposure of neutrophils to this chemoattractant induces the formation of 
pseudopodia and migration (Wright et al., 2010). 
*Also shown to be involved in PMN recruitment 
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Overall there seems to be an increased expression of cytokines in tumour bearing 
mice in comparison to control mice, suggesting that the primary tumour is affecting 
this secondary environment. The method used for this cytokine array, however, 
meant that it was not possible to show statistical significance of individual cytokines. 
Therefore, certain cytokines were chosen (based on antibody availability, 
expression pattern and role in pre-metastatic niche development) to be studied 
individually. To do this the pools were deconstructed and each tissue lysate sample 
was analysed via Western blot shown in Figure 3.3A. The expression of the proteins 
was quantified using FIJI and as an extra layer of accuracy, the results were 
normalised using the loading controls. 
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Figure 3: Pools were deconstructed to study the significance of cytokines of 
particular interest. 
Tissue lysates from the lungs of control mice and pre-metastatic lungs from 
β3IntegrinΔEC and WT (Cre-negative) mice were studied for the presence of P-
selectin, CCL6, CCL21 and a loading control, GAPDH (Control n=2, WT n=5, 
β3IntegrinΔEC n=5). (A) The loading control was used as a point of reference to 
normalise the results. (B) The levels of cytokines relative to the loading control 
was quantified using ImageJ (Mean + SEM; * p<0.05). 
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All these cytokines follow similar expression patterns to those described in the 
cytokine array which might support the trends suggested by the array. Of these three 
cytokines, however, only two of them have changes of expression in the different 
conditions and genotypes that is statistically significant following densitometric 
analyses.  
 
The first is P-selectin which plays an important role in the adhesion of leukocytes to 
the endothelium. The expression of this protein is significantly higher in β3 integrin 
positive tumour bearing mice in comparison to the control non tumour mice. There 
is also a significant decrease in the expression of this protein in the pre-metastatic 
niche when β3 integrin is depleted in endothelial cells. This suggests that there could 
be changes to populations of leukocytes in the pre-metastatic niche.  
 
There is also a significant increase in the expression of CCL21 in the tumour bearing 
mice compared to the control mice. As described in Table 2, when this protein is 
expressed in the pre-metastatic niche it can support the homing of metastatic cancer 
cells to this supportive environment. While there is no significant change in the 
expression of this protein with β3 integrin depletion the increased expression in 
tumour bearing mice could be taken as support of the presence of a pre-metastatic 
niche and the trends that the cytokine array suggests. 
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3.3 Leukocyte Populations in the Pre-Metastatic Lung 
 
The significant increases of P-selectin expression in WT tumour bearing mice in 
comparison to the others lead me to study how overall populations of leukocytes 
might be affected in the pre-metastatic lung. CD45 (a pan leukocyte marker) staining 
was utilised for this in flow cytometry and immunostaining of lung sections.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Overall populations of leukocytes in the pre-metastatic niche are 
not affected by the depletion of αvβ3 in endothelial cells.  
(A) Cryosectioned control and WT (Cre-negative) and β3flox/flox/Tie1-Cre 
(β3IntegrinΔEC) pre-metastatic lung were stained with CD45-FITC (green) and 
DAPI (blue). Images were collected and stitched using Zeiss Axioplan to prepare 
images of whole lung sections. (B) ImageJ was used to quantify the staining which 
was then normalised against the size of the lung section (Mean + SEM; Control 
n=2, WT n=3, β3IntegrinΔEC n=3; ns= no significance). (C) Flow cytometry using 
pre-metastatic WT and β3flox/flox/Tie1-Cre was used to find the number of CD45+ 
cells (WT n=4, β3IntegrinΔEC n=4). 
 
The pre-metastatic mouse model was once again exploited in this experiment using 
the CMT19T-F1 cell line. Primary tumours were grown for 3 weeks (to about 1cm3) 
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before mice were sacrificed allowing time for the pre-metastatic niche to develop. In 
figures 4A and B the lungs were inflated and embedded in gelatine before freezing 
in liquid nitrogen cooled isopentane. The samples were then cryosectioned and 
stained with DAPI (blue) and CD45-FITC (green), shown in Figure 3.4A.  To obtain 
an idea of the presence of CD45 in the pre-metastatic niche that was as accurate 
as possible the whole lung sections were analysed. To do this images were taken 
and then stitched together to get images of the whole lung, shown in Figure 3.4A. 
FIJI was then used to quantify the CD45 staining in the lung using a macro based 
on particle analysis, to keep consistency, eliminating background based on 
threshold, circularity and size. These results were normalised against the size of the 
lung section and are presented in Figure 3.4B. This figure shows no significant 
change in CD45 staining, and therefore leukocyte presence, in the pre-metastatic 
lung with β3 integrin depletion however these are again preliminary results and could 
be repeated. 
 
This result is supported by the analysis of CD45 in the pre-metastatic lung using 
flow cytometry. Once again using the CMT19T-F1 cell line for the pre-metastatic 
niche model the numbers of CD45+ cells in the pre-metastatic lung was analysed 
using flow cytometry gating to remove dead cells and cell debris. This also showed 
that β3 integrin depletion has no significant effect on leukocyte infiltration. 
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While Figures 3.4B and C show some small changes in the expression of CD45 in 
the pre-metastatic lung none of these are significant. Overall, the infiltration of 
leukocytes to the pre-metastatic lung does not seem to be affected by depletion of 
β3 integrin in endothelial cells. Since there is no general leukocytic change to the 
pre-metastatic niche, individual leukocyte lineages were studied.  
 
Figure 5: Knocking out αvβ3 in endothelial cells increases the number of PMN 
cells but not monocytes in the pre-metastatic lung.  
Pre-metastatic lung cells from WT (Cre-negative) and β3flox/flox/Tie1-Cre 
(β3IntegrinΔEC) mice were suspended and analysed using flow cytometry (Mean 
+ SEM; WT n=3, β3IntegrinΔEC n=3; ns = no significance, * p<0.05). (A) The 
first gate was used to remove dead cells and cell debris; the second gate was used 
to gate the CD45+CD11b+ populations. (B) The P1 gate identifies the PMN cells 
(C45+CD11b+Gr1hiLy6clo+int) and the mean numbers are shown in a bar graph (C) 
The P2 gate identifies Monocytes (C45+CD11b+Gr1lo+intLy6chi) in the lung with 
mean percentages represented in a bar graph. 
 
There are a number of myeloid subsets that infiltrate the tumour microenvironment 
including polymorphonuclear leukocytes and monocytes playing pro-tumorigenic 
roles (Elpek et al., 2014). It has been suggested that changes to the numbers of 
these cellular subsets in tissues can indicate the formation of a pre-metastatic niche 
(Batista et al., 2014).  
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To study these two fractions of CD45+CD11b+Gr1+ myeloid cells a series of gating 
was necessary (shown in Figure 3.5A). First dead cells and cell debris were gated 
out, secondly the CD45+CD11b+ fraction was gated onto, and thirdly the 
Gr1hiLy6clo+int – PMN (P1) and Gr1lo+intLy6chi – monocyte (P2) fractions were 
identified. These fractions as a percentage of CD45+CD11b+ in the pre-metastatic 
lung are presented in Figures 3.5B and C.  
 
Though the numbers of monocytes in the pre-metastatic lung increase in β3 
knockout mice this change is not statistically significant. There is, however, a small 
but significant increase in the numbers of PMN cells that colonise the pre-metastatic 
niche brought about by acute depletion of β3 integrin in endothelial cells. This 
phenotype is supported by the expression patterns of CCL-2 and -3 in the cytokine 
array. Since this is associated with an increase the number of metastases the results 
seem to suggest that this fraction may include cells with anti-tumorigenic functions, 
such as N1 or G1 cells.  
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4. Discussion 
 
4.1 Methodology 
 
4.1.1 Mouse Models 
 
This study has used a model that depletes αvβ3 in endothelial cells via tie-1 directed 
expression of Cre and floxing the β3 gene.  The role of αvβ3 is not isolated to 
endothelial cells however and there are studies looking at which tissues are effected 
by Tie1 directed Cre expression. To study this the tie-1-Cre model was crossed with 
ROSA26R-LacZ Cre reporter mice which leading to LacZ staining with Cre 
expression. This showed that apart from a strong expression of the promoter in the 
endothelium, post-natal neural and haematopoietic cells also expressed LacZ 
(Gustafsson et al., 2001). The latter of these, however, is not surprising given that 
endothelial cells share a common progenitor with haematopoietic cells known as the 
hemangioblast (Vogeli et al., 2006). 
 
The integrin αvβ3 can act as an adhesion molecule, supporting migration, or as a 
signalling receptor in the haematopoietic lineage which has been shown to affect 
the pre-metastatic niche. One study showed that knocking out β3 in macrophages 
supported tumour growth by increasing polarisation of macrophages to an M2 
phenotype by controlling STAT1/6 signalling. This study used the B6LV1 cell line 
(renamed PyMT-BO1) which will be discussed further in section 4.1.2 (Su et al., 
2016). Since platelets also express tie-1 (Tsiamis et al., 2000) this model may also 
lead to the depletion of the integrin αiibβ3 in these cells effecting the binding of tumour 
cells to platelets during circulation supporting metastasis. As such using this model 
could interfere with cancer related studies by depleting non endothelial β3 integrin. 
Gustafsson et al. (2001), show that the expression of αvβ3 in the haematopoietic 
lineage does diminish in adulthood. Due to the roles αvβ3 plays in non-endothelial 
cells (such as haematopoietic cells) in cancer progression a number of experiments 
were performed to confirm this. This gives further confirmation that αvβ3 depletion is 
isolated to endothelial cells and platelets are not affected in the tie-1-Cre model. On 
the other hand, Steri (2015; unpublished) showed that while CXCR4+ cells, an 
important subset in the pre-metastatic niche had no significant change in β3 
expression, the endothelial expression of β3 does significantly decrease in 
association with a number of haematopoietic markers including CD45 and Ly6G. 
This suggests that there is further need for confirmation that Cre expression (and 
therefore β3 depletion) is confined to endothelial cells. 
 
In order to confirm there is no non-endothelial depletion of β3 integrin a number of 
approaches could be used. Bone marrow reconstitution could be performed (as has 
been done in a study looking at the effect of αvβ3 on vascular leakage (Su et al., 
2012)). Performing metastasis studies after replacing the bone marrow of 
β3IntegrinΔEC mice with WT bone marrow could fully eliminate the possibility that 
depletion of haematopoietic β3 causes any phenotypic changes. Alternately a 
tamoxifen inducible knockout of αvβ3 in endothelial cells, β3 flox/flox/Pdgfb-
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iCreERT2 is available which does not express αvβ3 in the bone marrow. This would 
act to not only confirm results but also allows time specific deletion of endothelial β3 
integrin providing a model more akin to a therapeutic setting.  
 
4.1.2 Pinning Down the Development of the Pre-Metastatic Niche and 
Modelling it in Mice 
 
Mouse models are an essential part of translating research into a therapeutic 
intervention. An important part of developing models of the pre-metastatic niche is 
pinning down the exact point at which the niche develops. This prevents confusion 
of the pre-metastatic niche with the distinct, early metastatic niche which is 
influenced by the presence of tumour cells. 
 
The seminal article by Kaplan et al. (2005) used a spontaneous metastatic model to 
document the time it took for the pre-metastatic niche to develop and tumour cells 
to enter the niche. They showed that BMDCs started migrating to the lung twelve 
days after tumour implantation. At day fourteen clusters of BMDCs formed in the 
niche at future metastatic site. At day eighteen metastatic tumour cells associated 
with these clusters and these individual tumour cells grew to form micro metastases 
at day 23. This showed the progress of the future metastatic site from a pre-
metastatic niche to an early metastatic niche. This cannot be used across all 
spontaneous metastasis models however, as different cell lines and mouse models 
lead to a different metastatic process with different timescales and involve different 
cytokines and potentially BMDCS.  
 
The model I used for the pre-metastatic niche was developed by Steri (2015) and 
based on her model of spontaneous metastasis. The tie-1 Cre model (on a 
C57BL6/129Sv mixed genetic background) was used along with the CMT19T F1 
mouse cell line. This cell line was based on the CMT19T lung carcinoma cell line 
derived from CMT167 cells. To gain a cell line with a greater metastatic potential 
(CMT19T F1) the CMT19T cells were put through one round of in vivo selection of 
lung metastatic cells. These were injected subcutaneously (ectopically) to gain 
allograft primary tumours which would spontaneously metastasise to the lung. Since 
only this cell line has been used during this study only the lung pre-metastatic niche 
has been studied. To expand this further the PyMT-BO1 (used by Su et al., 2016) 
breast carcinoma cell line could be used which metastasises to both bone and lung. 
This cell line is particularly novel offering a spontaneous metastatic breast 
carcinoma model to bone. 
 
Using this model of spontaneous metastasis Steri (2015) measured that at day 
twenty cells began to colonise metastatic tissues. It is at this point in this metastatic 
mouse model that the primary tumours were resected. Based on this data, mice 
were sacrificed at this time to allow the study of the effects of endothelial β3 depletion 
on a developed and mature pre-metastatic niche.  
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There are issues with this model however as the interactions between the stroma 
and tumour are essential in cancer development. These subcutaneous injections 
are ectopic transplants that are not in the organ from which the cell line is originally 
derived. An important part of modelling cancer in mice is modelling all the stages of 
metastasis and ectopic transplants cannot fully represent the tumour environment 
(Saxena and Christofori, 2013). This is particularly significant when modelling the 
pre-metastatic niche which relies on signals from the primary tumour and its 
environment. It is also unclear whether reactions to therapeutic interventions in 
ectopic models will be the same as in orthotopic models (transplants in the tissue of 
origin) showing the shortcomings of these models (Francia et al., 2011).  
 
As mentioned before the time line established by Kaplan et al. (2015), does not 
traverse all pre-metastatic niche models. Variation among mice and cell lines 
changes how a tumour will develop and metastasise, therefore changing the timings 
of the pre-metastatic niche. As such, quantifying the time frame of the pre-metastatic 
niche must be done with each model. This makes the process of following these 
results up in a conditional knock out model (as confirmation of the role of endothelial 
β3 integrin in metastasis) harder.  
 
Even within a spontaneous model based on an orthotopic cell transplant there can 
be issues. One example is the use of cells line which by growing in vitro means that 
by passing them, cells can undergo changes and adapt to a 2D culture. They can 
also represent a specific clone rather than a heterogeneous population (Saxena and 
Christofori, 2013; Khanna and Hunter, 2005). This can lead to issues with replicating 
results and does not accurately model a human tumour. Another example is that by 
carrying out injections of cell this can cause an inflammatory response and may not 
model all the interactions between the environment and the tumour that have been 
shown to be essential (Khanna and Hunter, 2005).  
 
One way to create more refined models of metastasis that better demonstrate all 
the stages of the metastatic process would be to use genetically engineered mouse 
models of metastasis. This would generate orthotopic tumour without the need for 
injection in an immunocompetent environment better reflecting the interactions 
between the tumour and the host (Francia et al., 2011). One example of a genetically 
engineered model is the MMTV-PyMT breast cancer model (Khanna and Hunter, 
2005). These can be refined even further thanks to the advent of temporal and tissue 
specific knock out models such as MMTV-Cre; Trp53fl/fl which metastasises to the 
lung and liver (Saxena and Christofori, 2013). This can be extended to studying the 
pre-metastatic niche and should lead to a better translation between research and 
therapeutic interventions. 
 
Despite these options there are still issues, especially with modelling the pre-
metastatic niche, such as the fact that mouse organ tropism does not necessarily 
mimic human metastasis (Saxena and Christofori, 2013). This raises the question 
of whether a mouse model can ever truly mimic human disease? The inherent 
physiological difference between mice and humans may mean the answer is no and 
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as such perhaps other models with more human physiological and anatomical 
similarities such as dogs should be explored (Khanna and Hunter, 2005).  
 
4.1.3 Quantifying Immunohistochemistry  
 
Immunohistochemistry has many uses in identifying the expression of proteins by 
cells and tissues particularly in the field of pathology. Historically 
immunohistochemistry has been analysed by eye; choosing frames of an image and 
counting cells exhibiting staining or assessing the extent of staining by eye (e.g. 
grading via H&E staining). This is open to bias however, as the eye can be drawn 
to specific regions and since the results do not take into account the whole section 
results may not be accurate. A significant part of my time was devoted to finding a 
method I was able to use to quantify whole sections of the lung pre-metastatic niche.  
 
To quantify whole lung section, images of a lung section were taken at a 
magnification of x5, and stitched via Zeiss Axioplan software to get a complete 
image of the lung section, shown in Figure 3A. To reduce human error as much as 
possible an ImageJ macro with a standardised method was used. First the region 
of interest (ROI) was defined using a freehand tool to focus on the section itself and 
remove unnecessary parts of the image. This is used by a number of other 
quantification methods (Kokolakis et al., 2008; Arqués et al., 2012). A threshold 
value was then set using a standardised algorithm, Triangle, to eliminate any 
background and focus on the staining of interest. ImageJ provides a number of filters 
that can be used for different situations e.g. a greater intensity of staining (Jensen, 
2013). Finally, parameters were set to filter objects according to circularity and size. 
The values obtained from this analysis were then normalised against the ROI size 
to gain comparable values. 
 
An important part in this method is the normalisation of the staining value against 
the size of the ROI. There are a number of other methods that can be used to 
eliminate variation caused by differences in section size. One example is the division 
of the integrated density value (IDV) from a merged protein and nuclear stained 
image by the number of cells (gained from the nuclear staining value) to gain a value 
for protein expression vs cell number (Arqués et al., 2012). This method may 
produce a more accurate result as it uses the cell number instead of the size of the 
section to normalise values against and get comparable results. It also allows a 
wider application than the dot blot analysis (which identifies cells expressing 
markers by size and circularity) I have used. 
 
I have aimed to use whole sections in this analysis but there are now developments 
that allow the creation of a 3D image of tissues using microscopy. Quantification of 
this would produce an even more accurate picture of the presence of specific 
cells/expression of protein in tissues. Examples of quantification of 3D images are 
now described in the literature (Hirashima and Adachi, 2015) however this is an 
expensive procedure that requires significant expertise - given the limited timeframe 
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I had, balanced against cost, I felt the chosen method was a satisfactory 
compromise that would allow me to define areas for future focus. 
 
4.2 Endothelial Cells as a Barrier in Metastasis 
 
4.2.1 Permeability of the Endothelium 
 
The endothelium acts as a barrier to the movement of cancer cells in the metastatic 
cascade at both primary and secondary tissues. As such, changes to the 
permeability of the endothelium can increase the number of tumour cells entering 
and leaving the vasculature, thereby increasing the success of metastasis. There is 
some evidence that signalling from αvβ3 integrin could play a role in the process by 
inducing changes in endothelial permeability however findings are contradictory. 
 
There are suggestions that αvβ3 integrin negatively regulates permeability induced 
by VEGF-A, which affects adherens junctions by manipulating VE-cadherin. It has 
been shown that β3 integrin null mice have an increased sensitivity to VEGF-A 
mediated changes to endothelial permeability, which is put down to elevated levels 
of Flk-1. This suggests that αvβ3 integrin might enhance barrier function and 
therefore play an anti-metastatic role (Robinson et al., 2004).  
 
On the other hand, evidence from αvβ3 null mice suggests a pro-metastatic role for 
this integrin via permeability (Weis and Cheresh, 2005). The global deletion of this 
molecule contradicts the anti-metastatic phenotype of the tie-1Cre β3fl/fl model 
(presented in this dissertation). Part of this contradiction may, in fact, be due to the 
very fact that the study uses a global knockout of αvβ3 integrin whereas our results 
study the role of αvβ3 in endothelial cells specifically. The difference in mouse 
models may also lead to the contradictory results surrounding the role of αvβ3 in 
permeability, allowing the possibility of an endothelial specific pro-metastatic 
permeability. This is supported by evidence that in endothelial cells αvβ3 co-
operation with VEGFR-2 plays an important role in VEGF-A signalling (Soldi et al., 
1999; Mahabeleshwar et al., 2006).  
 
There are a number of proteins that are activated by αvβ3 co-operation with VEGFR-
2 that have a role in endothelial barrier function. One example is FAK which 
translocates to adherens junctions in endothelial cells upon stimulation by VEGF-A 
and enhances permeability by phosphorylating VE cadherin (Chen et al 2012; Jean 
et al 2014). Another example is c-Src which can also be stimulated by VEGF-A 
signalling, disrupting the association of VE cadherin with β catenin, leading to an 
increase in permeability and consequently metastasis (Criscuoli et al., 2005; Weis 
et al., 2004). This is supported by the suggestion that αvβ3 signalling in endothelial 
cells disrupts VE cadherin and consequently adherens junctions through 
phosphorylation of FAK and c-Src leading to an increase in permeability (Alghisi et 
al., 2009).  
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The results in section 3.1 suggest that the barrier function of endothelial cells is not 
affected by depletion of β3. This has been backed up by the fact that there are no 
changes in the numbers of circulating tumour cells in WT mice in comparison to β3 
integrin ΔEC mice (Steri, 2015; unpublished). This has only been studied using one 
method however and others could be used to confirm this result such as the Miles 
assay which uses Evans Blue to colour tissues with permeable vessels allowing the 
study of multiple tissues (Radu and Chernoff, 2013). Changes in permeability should 
also be investigated at the secondary site however as the primary tumour can 
influence the secondary site during pre-metastatic niche formation. This is an early 
event in the formation of the niche (Maru, 2015) supporting myeloid cell infiltration 
and later the extravasation of tumour cells. Potentially this could be supported by 
the increase in VEGF-A in the pre-metastatic niche of the lungs of WT mice 
suggested by the cytokine array. This result (suggesting an increase in VEGF-A) is 
preliminary however and experimental repeats would be necessary to determine if 
this is statistically significant. 
 
4.2.2 Adhesion of Cells to the Endothelial Layer Mediated by αvβ3 
 
An important part of trans-endothelial migration is the binding of the cell to the 
endothelial layer, a step which is relevant to both BMDCs and tumour cells. In some 
cases, metastatic growth starts upon adhesion to the endothelium in the secondary 
site growing into the tissue. By supporting the influx of BMDCs and tumour cells to 
the secondary site, adhesion is an important step in metastasis. When expressed 
by the endothelium αvβ3 certainly supports interactions with the ECM but could it 
also mediate cell-cell interactions as it does when it is expressed by certain myeloid 
populations and cancer cells? 
 
The vasculature of the primary tumour undergoes changes that differentiate it from 
the endothelium of the pre-metastatic niche. As such evidence suggesting primary 
tumour endothelium does not influence intravasation should not rule out the 
possibility of interactions between tumour cells and endothelial αvβ3 at the secondary 
site. There are a number of αvβ3 counter receptors expressed by tumour cells 
including L1 and PECAM-1. There is some evidence that the first of these can 
mediate interaction between tumour cells and endothelial αvβ3. A study showed that 
hypoxia, a state that can stimulate metastasis, increased the expression of αvβ3 in 
endothelial cells and antibodies targeting αvβ3 inhibited tumour cell adherence (Niu 
et al., 2007). 
 
In certain inflammatory situations it has also been suggested that endothelial αvβ3 
can regulate leukocyte attachment to the endothelium. For example, there is 
evidence that αvβ3 is upregulated when endothelial cells switch to an inflammatory 
phenotype (possibly due to inflammatory molecules) supporting the recruitment of 
certain leukocyte populations (Bechah et al., 2009). Another example is PECAM-1, 
which can interact with αvβ3, can be expressed by myeloid populations supporting 
leukocyte adhesion to the endothelium (Piali et al., 1995). This could potentially 
translate to a role for αvβ3 in the infiltration of immune cells into secondary organs 
supporting pre-metastatic niche formation. 
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These results are based on very specific examples but could translate to the pre-
metastatic niche which can be considered an inflammatory site (Maru, 2015) and is 
in part induced by hypoxia. If changes to the BMDC populations in the pre-
metastatic niche are identified these areas of study could lead to an explanation 
other than that suggested by the cytokine array (a significant increase in P-selectin 
in WT mice over control and β3 integrin ΔEC mice). 
 
 4.3 Immune Cells in the Pre-Metastatic Niche 
 
4.3.1 Changes in Myeloid (CD45+/CD11b+) Pre-Metastatic Niche 
Components with Depletion of endothelial β3 
 
The importance of BMDC mobilisation to the formation of the pre-metastatic niche 
has been demonstrated a number of times but as mentioned previously the 
haematopoietic signature of the niche is still being dissected. The experiments 
identifying changes to myeloid components of the lung pre-metastatic niche in this 
study have been based on a paper that studied how haematopoietic homeostasis 
can determine the success of metastasis. Two CD11b+/Gr1+ myeloid subsets were 
studied which are frequently referred to as MDSCs, the granulocytic (or 
polymorphonuclear (PMN)) subset, which is indicative of haematopoietic changes 
and the monocytic subset (Batista et al., 2014). In our studies only the PMN cells 
change significantly in the lung pre-metastatic niche increasing with depletion of β3 
integrin in endothelial cells. 
 
The MDSC population is derived from myeloid progenitor cells which differentiate 
into immature myeloid cells before entering circulation. Upon migration to peripheral 
organs these cells, depending on the environment of the tissue, will differentiate into 
mature myeloid cells (e.g. macrophages or neutrophils) or become an activated but 
immature subset known as MDSCs (Goedegebuure et al., 2011; Yang et al., 2013). 
This MDSC population also includes progenitors of granulocytes, macrophages and 
dendritic cells and when cultured these cells will differentiate into mature myeloid 
cells (Gabrilovich et al., 2012; Youn et al., 2012). As with other leukocyte 
populations, MDSC accumulation in the pre-metastatic niche is a response to a 
number of tumour derived factors including CCL2 and CXCL5 (Gabrilovich et al., 
2012). The cells are then activated by factors such as TGFβ, which can be found in 
the pre-metastatic niche, leading to the stimulation of a number of signalling 
pathways e.g. NFκB (Gabrilovich and Nagaraj, 2009). After activation they undergo 
expansion colonising the niche. This is again stimulated by tumour derived factors 
such as M-CSF and VEGF (Condamine et al., 2015). 
 
These cells have a prominent role in the pre-metastatic niche with a greater 
representation of the granulocytic over the monocytic subset. They play a number 
of roles in the niche regulating tumour invasion, angiogenesis and creating an 
immunosupportive environment for tumour cells (Talmadge and Gabrilovich, 2013). 
Of particular significance is the immunosuppressive role of MDSCs, thought to be 
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reliant upon factors such as arginase-1 and iNOS (Youn and Gabrilovich, 2010). 
MDSCs cause the activation and expansion of Treg cells and inhibit CD8+ T cell 
function so that they no longer respond to stimulation by antigens (Gabrilovich and 
Nagaraj, 2009). There has been debate over the immunosuppressive role of the G-
MDSC sub population however recently several papers have offered proof of Teff 
suppressive functions (Raber et al., 2014; Gabrilovich et al., 2012). 
 
Overall it is generally accepted that these cells play roles that support metastasis 
which is at odds with their increase in a model with decreased metastases. Despite 
this contradiction the trend is supported by a number of cytokines in the array such 
as CCL2 which recruits G/PMN-MDSCs and Mon-MDSCs to the pre-metastatic 
niche (Mitchem and DeNardo, 2012). As such this population of cells may be playing 
an alternative, anti-tumorigenic role in the niche that would decrease metastasis.  
 
In a number of leukocyte populations, a hetero-functionality has been observed due 
to a phenotypic polarisation induced by secreted factors. This supports an anti- or 
pro-inflammatory phenotype shown to be particularly significant in tumour biology. 
One example, the M1 (pro-inflammatory)/M2 (anti-inflammatory) functional axis, has 
been briefly described previously but this anti and pro-tumour polarisation does not 
only extend to macrophages. It is also evident in T cells and neutrophils and recently 
there have been suggestions of MDSC polarisation of both granulocytic and 
monocytic subsets (Yang, 2013). 
 
This is associated with the close relationship of MDSCs with mature myeloid cells, 
in fact some characterise G-MDSCs to be an immunosuppressive population of 
neutrophils (Coffelt et al., 2016). There is evidence that in certain inflammatory 
situations MDSCs, as with neutrophils are though to exhibit an N1 or N2 phenotype. 
At the tumour G-MDSCs can differentiate into to a tumour associated neutrophil 
(N2) phenotype, also referred to as G2 and though it is not clear what proportion of 
TANs are derived from G-MDSCs (Fridlender et al., 2012; Fridlender et al., 2009). 
As with neutrophils this possible polarisation/differentiation is suggested to be 
dependent upon TGFβ with its presence causing a G2/N2 shift in comparison to the 
G1/N1 shift with TGFβ antibodies (Yang et al., 2013; Yang, 2013). This polarisation 
of MDSCs from G2 to G1 leads to a reduction in their immunosuppressive functions. 
By repolarising the cells to an anti-tumour phenotype it could be possible to use 
them as an anti-tumour immunotherapy (He et al., 2016). 
 
This is the work of small n numbers and only one experiment therefore repeats 
would be necessary before relying upon this result. This also means that the change 
to the monocytic fraction should not be discarded with these cells also increasing 
with β3 depletion. The polarisation of G-MDSCs is still a theory with little to no 
evidence backing it up however Mon-MDSC polarisation is better established. As 
with G-MDSCs, Mon-MDSCs can differentiate to a TAMs when they enter the 
tumour micro-environment. This population of cells can polarise to an M2 phenotype 
with immunosuppressive properties e.g. M2 MDSC cause an increase in Treg 
function and decrease Teff function while the M1 MDSC phenotype leads to the 
opposite (Yang et al., 2013; Ma et al., 2011). Experiments have also been carried 
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out that repolarise Mon-MDSCs from an M2 to M1 phenotype leading to a loss of 
their immunosuppressive function (He et al., 2016). This, again, could be a 
promising therapeutic strategy in the future. 
 
4.3.2 Mature Myeloid cells in the Pre-Metastatic Niche and the 
Influence of Cytokines 
 
The greatest proportion of the pre-metastatic niche seems to be MDSCs however 
there are also a number of other myeloid cells, some of which have been mentioned 
in Figure 3.2. At the late stage of the pre-metastatic niche that this study focuses on 
a diverse range of cytokines would be expected and this is reflected in the cytokine 
array.  
 
There are a number of studies showing potential roles for the mature classes of 
myeloid cells which have been mentioned (e.g. neutrophils and macrophages). In 
pancreatic cancer, for example, MIF from the primary tumour leads to the secretion 
of TGFβ followed by fibronectin production. This lead to the arrest of bone marrow 
derived macrophages (identified by F4/80) and, to a lesser extent, neutrophils in the 
development of the pre-metastatic niche supporting metastasis (Costa-Silva et al., 
2015). Another study showed that neutrophil accumulation in pre-metastatic lungs 
increased in Ifnar1-/- mice and was associated with an increased success of tumour 
metastasis.  It was suggested that this was due to an increase in CXCR-2 
expression by neutrophils and G-CSF in serum allowing neutrophils to support 
extravasation and proliferation of tumour cells (Wu et al., 2015). 
 
As shown in these studies cytokines are an important part of determining the influx 
of these bone marrow derive myeloid cells and a number of cytokines involved in 
this process have been studied in the cytokine array Figure 3.2. There is a trend 
suggesting an increase of chemokines associated with neutrophil influx in WT mice 
compared to control and β3IntegrinΔEC mice. This trend is reflected by 
myeloperoxidase, CXCL-1, -2 and -5 and by complement component 5a. There are 
two outliers of this trend however, CCL-2 and -3, which are only expressed by 
β3IntegrinΔEC mice. The cytokines associated with macrophage infiltration in this 
array seem to tell a different story however, particularly CCL6 which shows a 1.4-
fold increase in β3IntegrinΔEC mice compared to WT. This trend and increase is 
reflected in the western blot, but it is shown to be insignificant. CCL-2, a cytokine 
which also supports macrophage infiltration and is known as macrophage 
chemoattractant protein 1, echoes this trend. This cytokine is particularly important 
as there are a number of studies that show it supports the formation of the pre-
metastatic niche. Secreted by the primary tumour this chemokine can encourage 
the mobilisation and expansion of MDSCs (Sceneay et al., 2013; Sceneay et al., 
2012). This function is therefore greatly at odds with its expression by β3IntegrinΔEC 
mice only.  
 
Overall the cytokine array shows a distinct presence of inflammatory and tumour 
supportive cytokines associated with tumour injection. The two genotypes then vary 
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greatly, expressing some cytokines equally and others at different levels. Apart from 
confirming the trends suggested in this array of cytokines such as VEGF-A by further 
experiments a number of other cytokines could also be studied in the pre-metastatic 
niche. One example is TGFβ which modifies the niche and may also suggest 
functional changes of neutrophils. Based on this both neutrophils and macrophages 
could be used to identify changes in the pre-metastatic niche. 
 
4.3.3 Immunomodulation in the Pre-Metastatic Niche 
 
As has been described, one of the most important functions of MDSCs in the pre-
metastatic niche is to provide an immunosuppressive environment that supports 
tumour growth. This is done by increasing Treg function and preventing the activation 
of Teff cells that will specifically target cancer cells. The main focus of this study, as 
with many studies of the pre-metastatic niche has been how β3 depletion could 
potentially support tumour metastasis via the immune system. This system is not 
only supportive however and can mount a response against a tumour. This is 
evident in the elimination relationship of the tumour with the immune system during 
immunosurveillance. As such an anti-tumour immune response could be explored 
in relation to endothelial expression of αvβ3 integrin. 
 
The roles of T lymphocytes, NK cells and APCs in the recognition of tumours as 
non-self and consequent elimination have been described in section 1.1.4. Markers 
identifying the cells could be used to study how these populations change in the pre-
metastatic lung using immunohistochemistry (as has been done with leukocytes and 
MDSCs in section 3). Examples of such markers include CD8a+ for dendritic cells, 
CD4+/CD45RA- T cells (eliminating the Treg population), and CD8+/CD107a+ to 
identify degranulating cytotoxic T cells (Miyara et al., 2009; Apetoh et al., 2015; 
Gajewski et al., 2013).  
 
Part of this anti-tumour function can be determined by cytokines that are found in 
an inflammatory environment. These signals are particularly important in the context 
of this study because of the role they play as messengers from the primary tumour 
setting up the pre-metastatic niche. Since there is no overall leukocyte increase any 
changes in T lymphocytes in the niche will probably be a specific mechanism such 
as cytokines which induce specific functional changes in immune cells. Some of 
these have been mentioned, including IFNγ, CXCL-9, -10, and -11 (which are all 
involved in Teff function). Identifying the expression of these cytokines in the pre-
metastatic niche could shed light on any change in the function of the immune 
system with endothelial αvβ3 depletion.  
 
4.4 Exosomes and the Pre-Metastatic Niche 
 
A more recent development in the understanding of the pre-metastatic niche has 
been the discovery of exosomes (or microvesicles) as messengers conveying 
information from the primary tumour. The development of a number of cancers is 
associated with exosome production allowing communication with other tissues to 
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create a tumour supportive environment (Zhang and Wang, 2015). In this vein these 
messengers have also been shown to be able to influence the cells of secondary 
tissues contributing to the formation of the pre-metastatic niche.  
 
Exosomes are small membrane bound vesicles created by cells that carry RNA and 
functional proteins. They can travel through the transport systems reaching distant 
tissues or move to nearby cells before fusing with them and transferring their load. 
This allows both distant and nearby cell to cell communication that can affect the 
cellular phenotype (Alderton, 2012). Tumour cells secrete exosomes into the 
surrounding microenvironment and the blood stream allowing them to communicate 
with surrounding and distant tissues, an advantage to tumour development. The 
number of exosomes that tumour cells secrete is in fact linked to the stage and 
invasiveness of a cancer (Peinado et al., 2011; Peinado et al., 2012). 
 
The secretion of the messenger vesicles by tumour cells into the blood stream led 
to interest in exosomes in regards to the priming of the pre-metastatic niche. It was 
suggested that the vesicles where a way of carrying tumour secreted factors (an 
important part of niche initiation) to the niche. A number of papers have now shown 
evidence to support this theory. One study injected mice with exosomes derived 
from tumour serum leading to an increased likelihood of metastasis. Analysis of the 
vesicles showed that they carried a number of pre-metastatic niche factors such as 
S100A9 and S100A9. They then studied changes of BMDC behaviour showing that 
exosomes educated BMDCs mobilising them leading to an increased number at 
pre-metastatic tissues (Peinado et al., 2012). Another study, also mentioned above, 
showed that pancreatic cancer could induce formation of a liver pre-metastatic niche 
by exosomes expressing MIF. Upon fusing with Kupffer cells the exosomes caused 
a change in the architecture of the tissue leading to the influx of BMDCs, a critical 
point in pre-metastatic niche formation (Costa-Silva et al., 2015). 
 
There are now a number of examples showing that exosomes secreted from the 
primary tumour can educate the pre-metastatic niche. There is also some evidence 
that part of this process involves a change in the phenotype of endothelial cells. As 
mentioned, an increase in permeability is an early event in the formation of the niche 
and it has been suggested that exosomes can play a part in this. They showed that 
exosomes released from breast cancer cells expressed miR-105 and fused with 
endothelial cells transferring this microRNA. Injection of these tumour derived 
exosomes into mice led to an increase of miR-105 in distant pre-metastatic organs 
followed by reduced endothelial expression of ZO-1 (which regulated endothelial 
adheren junctions) and a decrease in barrier permeability. This was accompanied 
by an increase in metastasis that was blocked by anti-miR-105 suggesting that miR-
105 released by tumour exosomes increased permeability of endothelial cells in the 
pre-metastatic niche (Zhou et al., 2014). 
 
For exosomes to induce changes in cells they must bind and fuse with them before 
unloading the proteins and RNA that they transport. Since αvβ3 is a transmembrane 
adhesion molecule it may be possible that it supports the adhesion and fusion of 
exosomes expression proteins with RGD motifs to endothelial cells. This could 
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potentially support the formation of the pre-metastatic niche and provide a 
metastasis supportive role for αvβ3. One study presented evidence suggesting that 
exosomes expressing ADAM15 bound to tumour αvβ3 in an RGD dependent manner 
leading to a decrease in tumour growth (Lee et al., 2012). Another study showed 
that dendritic derived exosomes bound to cells via their expression of αvβ3 integrin 
(Pitt et al., 2014).  
 
With the emergence of exosomes as an important mediator of primary tumour 
signals to the pre-metastatic niche this could be an interesting area to study as an 
explanation for the pro-metastatic effects of endothelial αvβ3. 
 
4.5 The Pre-Metastatic Niche and Therapeutic Intervention 
 
As metastasis is the cause of 90% of cancer related deaths (Sceneay et al., 2013) 
cancer research has entered a mind-set similar to Paget’s, that the focus of research 
should be understanding the metastatic process. Part of this has and will be 
understanding the pre-metastatic niche. There are now a number of researchers 
starting to look into how the pre-metastatic niche can be harnessed in therapeutic 
interventions reversing its phenotype as an environment receptive to metastasis.  
 
One strategy has been to selectively target cells within the BMDC clusters that form 
in the pre-metastatic niche. It has been suggested that selectively targeting 
VEGFR1+ BMDCs to prevent migration could enable a double hit targeting both the 
primary tumour environment (which also has VEGFR1+ HPCs) and pre-metastatic 
niche (Peinado et al., 2011). Alternatively, MDSCs could be targeted to reduce their 
immunosuppressive functions thereby enhancing anti-tumour immunity. One way to 
do this would be to induce MDSC differentiation, lowering their numbers and 
reducing their pro-tumour effects. This can be done with al-trans retinoic acid which 
induces their differentiation in to APCs or with a low dose of IFNγ (Talmadge, 2007; 
Zoccoli et al., 2012). It may also be possible to reverse the supressive effect of 
MDSCs on T cells by targeting proteins such as ARG1 and NOS2. In mice this has 
been shown to increase the number of anti-tumour T cells (Talmadge, 2007). 
Targeting the immunosuppressive function of MDSC’s could then be used in 
combination with immunotherapies, increasing their effectiveness (Ko et al., 2009).  
 
Another way of translating knowledge of the pre-metastatic niche into therapeutic 
interventions has been to target exosomes (which play an important part in 
educating the niche to support tumour cells). It is thought that of the many pathways 
cells can use for the secretion of exosomes, tumour cells use a mechanism based 
on Rab27a. Knocking down expression of this protein has resulted in a decrease in 
neutrophil mobilisation and metastasis in a breast cancer model and reduced 
metastasis and BMDC recruitment in a melanoma model (Vader et al., 2014). 
Another thought has been to use exosomes to enhance the anti-tumour immune 
response by priming T cells with exosomes carrying antigenic material. Clinical trials 
of this theory have been met with little success currently, possibly due to molecules 
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within the exosomes that have immunosuppressive properties (Peinado et al., 
2011). 
 
Better understanding of the pre-metastatic niche may not only lead to new therapies 
but also to an earlier detection of cancer metastasis, another important part in the 
survival of cancer patients. The detection of myeloid cluster could lead to an earlier 
identification of a patients’ inclination to metastasis than is currently possible. By 
identifying this proclivity towards metastasis at an earlier stage this may also lead 
to earlier therapeutic interventions, increasing the chance of patient survival (Psaila 
and Lyden, 2009).  
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